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Abstract 
Aim: To describe the prevalence of HIV infection, and the disease profile and outcome of 
440 HIV-infected children admitted to the general paediatric wards at Chris Hani 
Baragwanath Hospital (CHBH). 
Methods: A comprehensive list of all paediatic patients admitted to the general wards 
between October and December 2007 was compiled using hospital admission records. 
Hospital folder and laboratory records were used to determine HIV prevalence. A 
retrospective review of inpatient hospital records was conducted for all confirmed HIV-
infected paediatric patients admitted during the study period.  
Results: The prevalence of confirmed HIV infection amongst paediatric admissions at 
CHBH during the study period was 29.5% (95% CI 27.2 -31.9%). Of these children, 54.1% 
were newly diagnosed with HIV during the current hospital admission. Despite the 
majority (92.7%) of admissions having advanced HIV disease (WHO Stage 3 or 4), only 
17% were accessing ART. Of the 202/440 (45.9%) children known to be HIV-infected 
before hospital admission, only 74/202 (36.6%) were currently receiving ART. Of the 
remaining 128/202 children known to be HIV-infected before hospital admission, 121/128 
(94.5%) had WHO HIV stage 3 or 4 disease and thus were eligible for ART. Only 19% of 
children had a normal weight. Amongst infants aged less than 6 months uptake of PMTCT 
interventions was poor - only 36% of mother-infant pairs received single dose nevirapine 
and 28% of infants received cotrimoxazole prophylaxis. Respiratory illness was the 
principal reason for hospitalization in 37.5% of admissions.  Gastroenteritis, sepsis and 
tuberculosis accounted for 22%, 19.5% and 21% of principal diagnoses respectively.  The 
overall case fatality rate was 12% (95% CI 9.2–15.5%), with deaths in HIV-infected 
children contributing 58% of all deaths in the general paediatric wards. Over half (52%) of 
all deaths in the HIV-infected group occurred in infants younger than 6 months of age. 
  vi 
Conclusion: HIV infection remains a major contributor to morbidity and mortality among 
paediatric admissions at CHBH.  Poor uptake of PMTCT interventions, late diagnosis of 
HIV infection and delay in accessing ART are immediate barriers to improved care in HIV-
infected children at CHBH. The underlying reasons for poor accessibility and under- 
utilisation of paediatric HIV-related services requires further investigation.  Efforts to 
reduce mortality amongst HIV-infected paediatric admissions at CHBH should focus on 
early diagnosis of HIV infection and prompt initiation of antiretroviral treatment, especially 
in infants under 6 months of age. 
 
 
 
  vii 
Acknowledgements 
 
With thanks to: 
 my knowledgeable and supportive supervisors: doctors Ameena Goga, Tammy 
Meyers and Ashraf Coovadia 
 the Harriet Shezi Children‟s Clinic Research Group, especially Louise Kuhn and 
Matthew Cherisch for their advice and encouragement 
 the hospital records department and the Department of Paediatrics at CHBH for 
access to patient files 
 the University of the Witwatersrand Faculty of Health Sciences Research 
Committee for funding this study   
 
 
 
 
 
 
 
 
 
  viii 
Table of contents 
Title page________________________________________________________________ i 
Declaration_______________________________________________________________ii 
Dedication_______________________________________________________________iii 
Publications and presentations arising from this research__________________________ iv 
Abstract_________________________________________________________________ v 
Acknowledgements_______________________________________________________ vii 
Table of contents ________________________________________________________viii 
List of tables ____________________________________________________________  xi 
List of figures___________________________________________________________  xii 
Abbreviations___________________________________________________________ xiii 
Study Definitions________________________________________________________  xv 
Reference classifications _________________________________________________  xvi 
Case definitions________________________________________________________  xvii 
 
1. Introduction and literature review___________________________________________ 1 
1.1 Paediatric HIV – the International experience ________________________________ 1 
1.2 Paediatric HIV in South Africa – the scope of the epidemic______________________2 
1.3 Paediatric HIV in South Africa – impact on hospital admission profiles____________ 2 
1.4 Previous studies of Paediatric HIV infection at CHBH__________________________3 
1.5 Paediatric HIV in South Africa – role of the Child Healthcare Problem Identification 
Programme (Child PIP)_____________________________________________________ 4 
1.6 Prevention of Paediatric HIV in South Africa – the PMTCT programme___________ 5 
1.7 Management of Paediatric HIV infection in South Africa – the ART programme_____7 
1.8 Chris Hani Baragwanath Hospital and Harriet Shezi Children‟s Clinic_____________ 8 
1.9 Motivation for this study of the profile of Paediatric HIV infection at CHBH________9 
1.10 Aim of the study______________________________________________________11 
 
2. Materials and Methods __________________________________________________ 11 
2.1 Study design__________________________________________________________11 
2.2 Study population, methods and sampling___________________________________ 11 
2.2.1 Inclusion and exclusion criteria _________________________________________ 14 
2.3 Materials and Data collection____________________________________________ 15 
2.4 HIV testing___________________________________________________________17 
  ix 
2.5 Reference classifications________________________________________________ 17  
2.6 Case definitions_______________________________________________________ 18 
2.7 Statistical analysis plan_________________________________________________ 19 
2.7.1 Determination of HIV prevalence_______________________________________ 19  
2.7.2 Data entry and management for the HIV-infected sub-population______________ 19 
2.7.3 Statistical Methods___________________________________________________ 20 
2.7.4 Analysis describing the study population__________________________________20 
2.7.5 PMTCT Sub-analysis_________________________________________________ 21 
2.7.6 Determination of Case fatality rates______________________________________21 
2.7.7 Comparison of HIV-infected patient characteristics by final outcome___________ 21 
2.7.8 Comparison of HIV-infected patient characteristics by ART status_____________ 21 
2.8 Ethics clearance_______________________________________________________22 
 
3.Results _______________________________________________________________ 23 
3.1 HIV prevalence_______________________________________________________ 24 
3.2 Disease profile of confirmed HIV-infected paediatric admissions _______________ 25 
3.2.1 Demographics ______________________________________________________ 25 
3.2.2 Timing of HIV diagnosis amongst HIV-infected children ____________________ 26 
3.2.3 Self-reported access to PMTCT services  _________________________________ 26 
3.2.3.1 Self reported maternal HIV status______________________________________ 26 
3.2.3.2 Nevirapine exposure________________________________________________ 27 
3.2.3.3 Cotrimoxazole prophylaxis___________________________________________ 27 
3.2.3.4 Place of birth______________________________________________________ 29 
3.2.3.5 PMTCT interventions by maternal self-reported HIV status__________________31 
3.2.3.6 Missed opportunities for PMTCT interventions___________________________ 32 
3.2.4 Nutritional status ____________________________________________________ 34 
3.2.5 HIV staging ________________________________________________________ 36 
3.2.6 Antiretroviral treatment (ART) _________________________________________ 37 
3.2.7 Immunological indices _______________________________________________ 39 
3.2.8 Primary diagnosis ___________________________________________________ 42 
3.2.9 Spectrum of infectious pathogens _______________________________________ 44 
3.2.10 Outcome of HIV-infected paediatric admissions at CHBH __________________ 46 
3.2.11 Cause of death in HIV-infected paediatric admissions at CHBH ______________ 51 
3.2.12 Comparison of groups by ART status ___________________________________ 52 
  x 
4. Discussion and Conclusion _______________________________________________ 54 
4.1 Limitations___________________________________________________________54 
4.2. Strengths of the study__________________________________________________ 55 
4.3 HIV prevalence _______________________________________________________ 56 
4.4 Prevention of mother to child transmission (PMTCT) _________________________ 60 
4.4.1 Poor record-keeping__________________________________________________ 60 
4.4.2 Maternal self-reported HIV status_______________________________________ 60 
4.4.3 Nevirapine exposure__________________________________________________61 
4.4.4 Cotrimoxazole prophylaxis_____________________________________________62 
4.4.5 Missed opportunities for PMTCT interventions_____________________________62 
4.5 Nutritional status and HIV staging________________________________________ 64 
4.6 Antiretroviral treatment (ART) __________________________________________ 65 
4.7 Immunological indices _________________________________________________ 66 
4.8 Primary diagnosis______________________________________________________67 
4.9 Spectrum of infectious pathogens_________________________________________ 67 
4.10 Outcome ___________________________________________________________ 68 
4.10.1 Contribution of HIV-related deaths to overall paediatric mortality_____________ 68 
4.10.2 Outcome in young infants_____________________________________________69 
4.10.3 Outcome of ICU intervention in HIV-infected children _____________________ 69 
4.10.4 Step-down care at CHBH_____________________________________________ 70 
4.10.5 Comparison of HIV-infected patient characteristics by final outcome__________ 70 
4.11 Comparison of groups by ART status_____________________________________72 
4.12 Eligibility for ART in HIV-infected children who died_______________________ 73 
4.13 Conclusion__________________________________________________________74 
4.14 Recommendations for management of Paediatric HIV________________________76 
 
5. References ___________________________________________________________ 79 
 
6.Appendices____________________________________________________________ 86 
Appendix 1: Study tool ____________________________________________________86 
Appendix 2: WHO HIV Staging Criteria ______________________________________ 87 
Appendix 3: Ethics clearance certificate ______________________________________ 88 
Appendix 4: CHBH Letter of permission______________________________________ 89 
Appendix 5: Supervisors' certificate of submission_______________________________90 
  xi 
List of tables                                                                                                                    Page 
Table 1.  HIV prevalence amongst paediatric admissions at CHBH__________________24 
Table 2. Breakdown of PMTCT interventions in infants less than 6 months of age _____ 29 
Table 3.  PMTCT interventions in infants less than 6 months old by place of birth _____ 30 
Table 4. Comparison of NVP and CTX prophylaxis uptake in infants less than 6 months of 
age by self-reported maternal HIV status______________________________________ 31 
Table 5.Median weight for age z-scores by age category in months__________________35 
Table 6.  WHO HIV staging of paediatric admissions at CHBH____________________ 36 
Table 7. WHO HIV staging criteria for paediatric admissions at CHBH______________ 37 
Table 8.  Median CD4 percentages classified by age group in months and proportion of 
CD4 percentages less than 25%______________________________________________40 
Table 9.  Median CD4 count classified by age group in months and proportion of CD4 
percentages below 500 cells/ul______________________________________________ 41 
Table 10.  Primary  diagnoses_______________________________________________ 42 
Table 11.  Spectrum of infectious pathogens____________________________________44 
Table 12.  Spectrum of Infectious Pathogens in 53 HIV-infected children who died_____45 
Table 13.  Primary Diagnoses of 13 HIV-infected children admitted to ICU___________47 
Table 14. Case fatality rate by age group______________________________________ 49 
Table 15. Comparison of HIV-infected patient characteristics by outcome ___________ 50 
Table 16. Comparison of HIV-infected patient characteristics by ART_______________52 
Table 17. Eligibility for ART versus ART access in HIV-infected children who died ___ 53 
Table 18. HIV prevalence data from studies of paediatric admissions at CHBH________58 
 
 
  xii 
List of figures                                                                                                                   Page 
Figure 1.  Schematic overview of the study population____________________________23 
Figure 2.  Age distribution of 440 HIV-infected paediatric admissions_______________ 25 
Figure 3. Missed opportunities for PMTCT interventions__________________________32 
Figure 4. Missed opportunities for PMTCT interventions _________________________ 33 
Figure 5. Wellcome classification of HIV-infected children________________________34 
Figure 6. Antiretroviral treatment____________________________________________ 39 
Figure 7. Principal reasons for hospitalisation___________________________________43 
Figure 8. Classification of death by age group in HIV-infected children______________ 48 
Figure 9. Causes of death in HIV-infected children______________________________ 51 
          
  xiii 
Abbreviations 
AIDS                 Acquired immune deficiency syndrome 
ART                   Antiretroviral treatment 
CDC                  Centers for Disease Control 
CHBH                Chris Hani Baragwanath Hospital 
CHER                Children with HIV Early Antiretroviral Therapy trial  
Child PIP           Child Healthcare Problem Identification Programme 
CI                       Confidence interval 
CSF                    Cerebrospinal fluid 
CTX                   Cotrimoxazole 
EPTB                 Extrapulmonary tuberculosis 
ESBL                 Extended-spectrum beta-lactamase producing organism 
FTT                    Failure to thrive 
HAART             Highly active antiretroviral therapy  
HIV                    Human immunodeficiency virus 
HIVAN              HIV-associated nephropathy 
HIVISS              HIV Impact Surveillance Study 
ICU                    Intensive care unit 
IQR                    Interquartile range 
IRIS                   Immune reconstitution inflammatory syndrome 
MAC                 Mycobacterium avium complex 
MRSA               Methicillin-resistant Staphylococcus aureus 
NHL                  Non-Hodgkins lymphoma 
NHLS               National Health Laboratory Service 
NVP                  Nevirapine 
  xiv 
PCR                  Polymerase Chain Reaction test 
PHRU               Perinatal HIV Research Unit  
PJP                   Pneumocystis jiroveci pneumonia 
PMTCT            Prevention of mother to child transmission 
RTHC              Road to Health Card 
TB                   Tuberculosis  
pTB                 Pulmonary Tuberculosis 
VCT                Voluntary counselling and testing 
Wits                University of the Witwatersrand 
WHO              World Health Organisation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  xv 
Study Definitions 
Several definitions for the following terms can be found in the medical literature.  However 
for the purposes of this dissertation the definitions listed below were utilized. 
 
HIV-exposed: mother known to be HIV-infected and infant‟s status as yet unknown.   
HIV-unknown: no confirmed HIV result available for mother or child from laboratory and 
hospital records. 
HIV-negative: a non-reactive HIV PCR in an infant less than 18 months old or a non-
reactive HIV Elisa test in a child greater than 18 months old.  Since this 
study was retrospective, only mothers‟ self-reported HIV status could be 
recorded.  Thus it was not possible to accurately document what proportion 
of the HIV negative children had been HIV-exposed. 
HIV-infected: a reactive HIV PCR in an infant less than 18 months old or a reactive HIV 
Elisa test in a child greater than 18 months old. 
Maternal HIV status: Owing to the retrospective study design, only mothers‟ self-reported 
HIV status could be recorded. 
Nevirapine exposure: NVP exposure was said to have occurred if it was documented in the 
hospital record that either mother or infant or both had received NVP. 
Cotrimoxazole prophylaxis: A child was considered to be receiving CTX prophylaxis if the 
hospital record documented that the child was on CTX immediately prior to 
the hospital admission. 
 
  xvi 
Reference classifications  
Wellcome classification: This classification developed by the Wellcome Trust International 
Working Party on childhood malnutrition was utilised for categorization of nutritional 
status of HIV-infected children in this study.
1
 
 
WHO Clinical staging: (see Appendix 2) This staging system can be used for all children 
aged under 15 years with confirmed laboratory evidence of HIV infection. The revised 
2004 version (as it appears in the “Guidelines for the management of HIV-infected 
children” was utilised for classification of children in this study.2  
 
WHO growth references: This study utilised the 2006 WHO standards for assessing the 
growth and development of children from birth to 5 years of age.
3, 4
 
 
  xvii 
Case definitions 
Pneumocytsis jiroveci Pneumonia (PJP): A working clinical diagnosis of PJP at CHBH was 
considered in HIV-infected infants who fulfilled two or more of the following criteria: 
oxygen saturations less than 90% on admission or if ventilated, requirement of FiO2 >0.4 
for 4 or more consecutive days plus a respiratory rate > 60/minute, minimal findings on 
chest auscultation and a reticulonodular infiltrate on chest radiograph. These criteria are 
based on local teaching and the WHO clinical case definition of PJP.
5
 
 
Pulmonary Tuberculosis (pTB): A working clinical diagnosis of pTB at CHBH was 
considered in HIV-infected infants and children who fulfilled at least 2 of the following 
criteria: persistent cough for more than 2 weeks and/or fever for more than 1 week and/or 
recent failure to thrive, a history of a current TB contact, a positive tuberculin skin test 
(defined as induration > or equal to 5mm) and a suggestive chest radiograph or persistent 
infiltrates or lymphadenopathy on serial chest radiographs. 
  
Immune reconstitution inflammatory syndrome (IRIS): A working clinical diagnosis of 
IRIS at CHBH was considered in HIV-infected infants and children who fulfilled the IRIS 
case definition recommended in the “Guidelines for the management of HIV-infected 
children”: a paradoxical clinical deterioration within 6 weeks of starting ART, with new 
symptomatic infection with pathogens reported to be associated with IRIS, particularly 
Mycobacterium tuberculosis, Mycobacterium avium complex , Mycobacterium bovis (BCG 
reactions) and Cytomegalovirus (CMV) infections amongst others.
2
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1. Introduction and literature review      
1.1 Paediatric HIV – the International experience  
Internationally, low-income, high-HIV prevalence countries have documented the adverse 
impact of paediatric HIV/AIDS on child health indicators.  Under-five mortality rates are 
high in Malawi and India at 188 and 78 respectively, with paediatric HIV being a major 
contributor to child deaths.
6
  A prospective study of HIV infection among paediatric in-
patients in Blantyre, Malawi, documented HIV prevalence of 18.9% and high rates of 
malnutrition, lower respiratory tract infections and sepsis.
7
  Mortality rates approached 
30% among HIV-infected children in the study, a three fold higher rate than that observed 
among HIV-uninfected children in the same cohort.
7
   A prospective study of the clinical 
profile of paediatric HIV infection from India described very high rates of protein-energy 
malnutrition among a group of 42 HIV-infected children.
8
 Gastrointestinal and respiratory 
system illnesses were the principal reasons for hospitalisation among these HIV-infected 
children.
8
  
 
In high-income, low-HIV burden countries such as the United Kingdom (UK) and Ireland, 
HIV has had much less of an impact on the profile of paediatric hospital admissions.  A 
well-functioning prevention of mother to child transmission (PMTCT) programme and an 
increasing proportion of HIV-infected children accessing antiretroviral therapy (ART), 
resulted in an absolute decrease in hospital admissions of 26% between 1997 and 2002.
90
 
Data showed that up to 60% of HIV-infected children from a cohort of 944 had been born 
abroad.
9
 In a review of advances in paediatric HIV management, Sharland et al report that 
at the time of publication in 2002, there were around 600 children living with HIV in the 
UK.
10
 With the routine availability and high uptake of ART, the authors state that in the 
UK, HIV has become another treatable chronic disease of childhood.
10
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1.2 Paediatric HIV in South Africa – the scope of the epidemic 
The 2006 UNAIDS report on HIV/AIDS states that South Africa has one of the highest 
HIV seroprevalence rates in sub-Saharan Africa.
11
 At an 18.8% HIV seroprevalence rate, 
this translates into an estimated infected population of 5,4 million people.
11
  Of these cases, 
approximately 240 000 are HIV-infected children
11
, who suffer a disproportionately high 
burden of HIV-related morbidity and experience mortality rates double that of their HIV-
negative counterparts.
7, 12
  Past advances in child mortality rates have been reversed by the 
paediatric HIV epidemic in South Africa, making attainment of the Millennium 
Development Goals for Child Health improbable, if not impossible.
12
 
 
1.3 Paediatric HIV in South Africa – impact on hospital admission profiles 
The impact of paediatric HIV on hospital admission rates and profiles has been 
documented at many public hospitals in South Africa.  In Kwa-Zulu Natal, Pillay et al 
recorded a 62.5% HIV prevalence rate among children admitted to a tertiary general 
paediatric ward during a cross-sectional study of one month‟s duration.13 A 20% case 
fatality rate was reported among HIV-infected infants during the same period.
13
   In the 
Western Cape, a retrospective review of HIV-infected infants admitted at a tertiary hospital 
noted that infants under 6 months of age contributed 43% of all paediatric HIV-related 
admissions and suffered a high case-fatality rate of 13.5%.
14
   In both studies pneumonia 
was the main reason for hospitalisation.  At a tertiary hospital in Bloemfontein, a review of 
admission data from the years 1991 and 2001 was compared. Substantial increases in rates 
of pneumonia, malnutrition and overall mortality were attributed to the effect of HIV 
disease on the paediatric patient  population.
15
   Similar findings have been published from 
a rural, district hospital in Hlabisa, Kwa-Zulu Natal, where a prospective study of 
paediatric admissions documented a 25% HIV prevalence rate.
16
 The same study also 
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described higher rates of malnutrition and death from diarrhoeal disease and pneumonia in 
HIV-infected children.   
 
1.4 Previous studies of Paediatric HIV infection at CHBH 
Three previous studies at CHBH have described the local impact of HIV on paediatric 
hospital admission patterns.  Zwi et al conducted a retrospective study in the Department of 
Paediatrics at CHBH that documented the rapid rise of HIV prevalence among hospitalised 
children from 3% in 1992 to 19% in1996.  It was also demonstrated that over the same 
period, although mortality rates among HIV-uninfected children had declined, mortality in 
HIV-infected children increased dramatically from 6.7% to 46.1%.
17
  This study used 
computerized hospital discharge summary data only and at the time of the study HIV PCR 
testing was not available, thus limiting the reliability of the data used for HIV prevalence 
calculations. The study lacked a comprehensive description of the HIV-infected sub-
population, but did include information on a comparison group of HIV-negative and HIV-
unknown children 
 
In 1996 - before the commencement of the national Department of Health‟s PMTCT 
programme and before ART became available in the public sector - Meyers et al conducted 
a prospective study to determine paediatric HIV prevalence and clinical spectrum of 
disease at CHBH.  Over a 6 month period, serial pediatric admissions to a single ward were 
screened for HIV, enrolling a total of 549 patients. The study documented an estimated 
HIV prevalence among hospitalized children of 29%, recorded a mortality rate of 17% 
among the HIV-infected children and cited infectious diseases (pneumonia and 
gastroenteritis) as the most common reason for hospital admission.
18
  A comparison group 
of HIV-uninfected children was included.  HIV PCR results were missing or indeterminate 
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in up to 50% of HIV Elisa-positive children aged 15 months or younger and thus again, the 
prevalence calculations for this study were based on incomplete data.  
 
The cross-sectional HIV Impact Surveillance System (HIVISS) study was conducted in 
2005 by the University of the Witwatersrand (Wits) School of Public Health and the 
Gauteng Department of Health. The study aimed to establish a surveillance system for 
monitoring the impact of HIV/AIDS on health services in Gauteng.  Sentinel sites for 
collection of data on adult and paediatric admission profiles were established at several 
provincial clinics and hospitals including CHBH. Unpublished data from this study 
reflected a 31.5% HIV prevalence and a high mortality rate of 24.3% among HIV-infected 
children admitted to the general wards at CHBH. 
19
  One of the strengths of this study was 
that a 95% uptake of HIV testing was achieved at CHBH for paediatric admissions during 
the study period and that in only 2% of cases, a diagnosis of HIV-infection was based only 
on a history of HIV-exposure and clinical stigmata.  The study was designed to calculate 
HIV prevalence and quantify the impact of HIV on paediatric services.  There was very 
limited descriptive data available for HIV-infected children. 
 
1.5 Paediatric HIV in South Africa  
– role of the Child Healthcare Problem Identification Programme (Child PIP) 
In response to the increasing burden of care and child mortality rates in South Africa 
(largely attributable to paediatric HIV) the concept of the Child Healthcare Problem 
Identification Programme (Child PIP) was developed.  Child PIP assists in monitoring the 
quality of care delivered to South African children by documenting all inpatient paediatric 
deaths, assigning cause of death, recording nutritional and HIV status and identifying 
modifiable factors for each child death.  There are currently 57 hospitals from district to 
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tertiary level participating in the programme and contributing data which is analysed at 
local and national level to identify problems and generate recommendations for paediatric 
healthcare improvements. 
 
Recent data from countrywide Child PIP (2005-2007) – which is used in more than 50 
health facilities in South Africa - showed that of hospitalised children tested for HIV, 80% 
were either HIV-exposed or HIV-infected.
20
  However, many hospitalised children did not 
receive HIV testing and HIV status was recorded as unknown in 46% of all deaths at Child 
PIP sites.  Of known cases of paediatric HIV, 50% of children who died were assessed as 
WHO stage 3 or 4 and were thus eligible for ART, yet only 3% of these children were 
accessing ART.
20
   Child PIP data from 28 sites showed that HIV/AIDS was responsible 
for 35% of under-five deaths.
12
  Notwithstanding the availability of Child PIP data, 
information regarding paediatric HIV-related morbidity and mortality in South Africa is 
incomplete; for example, CHBH – the largest tertiary, public hospital in the country with a 
sizeable paediatric HIV/AIDS service – does not contribute data to the Child PIP records. 
Thus for clinicians and public health personnel working at CHBH, it is important to 
document the prevalence and impact of paediatric HIV at this large hospital. 
 
1.6 Prevention of Paediatric HIV in South Africa – the PMTCT programme 
The South African approach to preventing infant HIV infection is based on the 4-pronged 
comprehensive approach suggested by World Health Organisation and UNAIDS: primary 
prevention of HIV in parents-to-be; reduction of unwanted pregnancies; intensification of  
programmes to prevent mother-to-child transmission of HIV and provision of  appropriate 
treatment and care to women living with HIV as well as their children and families.
21
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Most HIV-infected children are vertically infected by mother-to-child transmission both 
perinatally (during labour and delivery) and postnatally (through breastfeeding.)
22
   In 
South Africa the antenatal HIV prevalence in the 2007 national survey was estimated at 
28%.
23
   In the absence of any preventative interventions, the risk of HIV transmission to 
the baby is about 25-35%.
24
    In developed countries with established prevention 
programmes, that include dual therapy, modified obstetric practices (mainly caesarean 
section deliveries), and replacement feeding, the rate of HIV transmission from mother to 
child has been curtailed to less than 2%.
25
  This statistic reinforces the fact that paediatric 
HIV is an eminently preventable disease. However, in South Africa, as in the rest of sub-
Saharan Africa, the burden of paediatric HIV continues to grow as a result of the 
uncontrolled adult HIV epidemic and poor functioning of the prevention of mother-to-child 
transmission (PMTCT) programmes.
26
  According to The United Nations Children's Fund 
(UNICEF), 300,000 infants are born to HIV-infected mothers annually, resulting in 
approximately 93,000 new paediatric HIV infections in South Africa each year.
26
   
 
Universal access to PMTCT in South Africa is not a reality and even in regions where 
PMTCT progammes are established, multiple programmatic weaknesses are identified.  
Some of these problems include low uptake of PMTCT amongst HIV-positive pregnant 
women, poor record keeping and high loss to follow-up of HIV-exposed infants.
27, 28
  From 
the perspective of South African paediatricians and researchers who seek to prevent new 
cases of paediatric HIV, universal coverage and intensification of current PMTCT 
programmes could achieve a radical reduction in the numbers of newly HIV-infected 
children in South Africa.
29
  For infants born to HIV-infected mothers, early testing would 
afford the opportunity to provide cotrimoxazole prophylaxis (to prevent early mortality 
from Pneumocystis jirovecii pneumonia) and ART to infected infants. 
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1.7 Management of Paediatric HIV infection in South Africa – the impact of the ART 
programme 
Although comprehensive paediatric HIV care, including access to ART is available at 
selected, largely urban-based centres in South Africa, the vast majority of HIV-infected 
children in South Africa are not accessing ART.
30
   In 2006, Department of Health 
estimated that over 21000 children under 14 years of age in South Africa were accessing 
ART. This reflects 10% of the total population on ART in the country, falling short of the 
15 % target set for proportional representation of children in ART programme coverage.
31
  
Access to paediatric ART programmes also varies widely between provinces and districts 
within provinces of South Africa. Of particular concern is the fact that many paediatric 
ART programmes are based at tertiary hospitals and are run primarily by paediatricians and 
medical officers.  In order to make paediatric ART more accessible, it is necessary to 
decentralise services and train primary care nurses to initiate and monitor children on ART.  
Although the National Department of Health is implementing the IMCI Complementary 
Course on HIV for nurses this has not translated into shifting or sharing the task of 
paediatric ART initiation and monitoring  to nurses or to primary care level, nationally. The 
latter model, however, has been successfully achieved in the Western Cape, where the 
proportion of children receiving ART at tertiary hospital level has decreased from 78% in 
2004 to 38% in 2006, due to ART initiation and monitoring at lower levels of the health 
care system.
30
  
 
An international study in a resource-poor setting (Thailand) has reported significant 
reductions in admission rates and mortality rates in children commenced on highly active 
anti-retroviral therapy (HAART).
32
   Similarly, the Children with HIV Early Antiretroviral 
Therapy (CHER) study, demonstrated that ART initiated before clinical and immunological 
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HIV disease progression, reduces early mortality in HIV-infected infants.
33
  Thus urgent 
scaling up of paediatric ART provision is needed so that all children in need of ART are 
able to access it timeously. Even in older children with advanced HIV disease, ART has 
been shown to improve survival.
34
   
 
Although some paediatric ART programmes in South Africa have published service audit 
data, few have commented on the effect of ART in reducing paediatric hospital admission 
rates.
35-37
  More data on the impact of ART provision on hospital admission trends in 
paediatric wards is needed in order to advocate for urgent upscaling of paediatric ART 
provision and better PMTCT services. 
 
1.8 Chris Hani Baragwanath Hospital and Harriet Shezi Children’s Clinic 
The study site, CHBH, is a tertiary government (public) hospital situated in Johannesburg, 
in the Gauteng province of South Africa.  CHBH is one of the largest hospitals in the 
southern hemisphere and provides services to the burgeoning urban township population of 
Soweto (last official population estimation of 1 million in 1996.)
38
  A significant proportion 
of paediatric inpatients at CHBH originate from other areas of Johannesburg and from 
beyond the Gauteng provincial boundaries.  The hospital has a total of 140 beds for general 
medical paediatric admissions under 14 years of age, with approximately 6000 paediatric 
admissions annually. (J.M.Pettifor, Head of Paediatrics Department, CHBH, personal 
communication, May 2008)  
 
A dedicated paediatric HIV clinic, Harriet Shezi Children‟s Clinic (part of the Wits 
Paediatric HIV Clinics) operates from the hospital.  This clinic provides outpatient services 
to 3356 HIV-positive children, of whom 2383 are presently on ART. (L. Fairlie, Head of 
  9 
Clinical Services, Harriet Shezi Children‟s Clinic, CHBH, personal communication, April 
2008)  HIV-infected children who are found to be in need of hospitalisation during their 
clinic follow-up consultations or at an outpatient clinic, are referred to CHBH general 
paediatric admission ward and, following discharge, are then followed up by the HIV 
clinic. 
 
1.9 Motivation for this study of the profile of Paediatric HIV infection at CHBH 
Continued surveillance of the prevalence and disease profile of HIV-related paediatric 
admissions at CHBH is an important task.  CHBH is the only state hospital delivering 
tertiary care to the population of Soweto. Thus monitoring of the paediatric admission 
profile at this sentinel site provides valuable information about the impact of HIV/AIDS on 
the wider Soweto community.  With scaling-up of ART and PMTCT provision, useful 
information regarding the impact of these programmes may be gained by continued 
monitoring of inpatient paediatric HIV-related morbidity and mortality.      
 
In order to assess Gauteng province‟s success in implementing the goals of the HIV & 
AIDS National Strategic Plan for 2007 - 2011, detailed information on specific health 
targets will be needed.  Data from ongoing surveillance of the paediatric HIV profile at 
CHBH (and other Gauteng hospitals) is an exercise that could assist with planning of 
services and contribute to a provincial database. This resource could be used to identify 
programmatic problems and measure progress in facilities providing paediatric HIV care.   
For example, monitoring the incidence of paediatric HIV (as measured by the number of 
new cases diagnosed at CHBH) would reflect on the effectiveness and coverage of the local 
PMTCT programme.  Data on rates of PCR testing of HIV-exposed infants and provision 
of CTX prophylaxis can provide insight into the coverage and quality of health services for 
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infants.  Data on rates of paediatric HIV testing, ART initiation and case fatality would also 
be valuable indicators in the assessment of HIV treatment programmes for children.
39
 
 
Single cross-sectional and retrospective studies can only provide “snap-shots” of the impact 
of HIV on paediatric health services at CHBH at specific points in time. Collectively, 
however, such studies are indispensable in allowing for data comparison and establishment 
of long-term trends, as long as study methods and definitions used are similar.  Data from 
periodic surveillance of paediatric HIV at CHBH should be used to assist with strategic 
planning and improvement of paediatric HIV services, both locally and at provincial level. 
 
This study is needed to provide more recent information on the profile of HIV-infected 
children admitted at CHBH, in the context of a national programme to prevent mother-to-
child transmission of HIV, and a national antiretroviral treatment programme. Prior to this 
study, the 1996 study by Meyers et al was the most recent study documenting HIV 
prevalence amongst children at CHBH.  Although previous studies
17, 18
 at CHBH included 
information on HIV-uninfected comparison groups, none provided in-depth and 
comprehensive data on the profile of HIV-infected children. Furthermore these previous 
studies were conducted prior to the roll out of a national programme to prevent mother-to-
child transmission of HIV, and a national antiretroviral treatment programme. This study 
includes analysis of information regarding access to and utilisation of PMTCT 
interventions (although limited by lack of data) and access to HAART and this is an 
important difference between previous studies and this study.   
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1.10 Aim of the study 
To determine the prevalence of HIV infection amongst paediatric inpatients and to describe 
the disease and demographic profile of HIV-infected children admitted to the general 
paediatric ward at CHBH. 
 
2. Materials and Methods 
2.1 Study design 
A retrospective, descriptive survey with analytic components was conducted between 1
st
 
April and 1
st
 May 2008, using the hospital records of all HIV-infected children admitted at 
CHBH from 1
st
 October 2007 to 31
st
 December 2007.  The prevalence of HIV infection and 
the disease and demographic profile of HIV-infected children admitted to the general 
paediatric wards at CHBH during the study period was described.   
 
2.2 Study population, methods and sampling 
All consecutive admissions to the CHBH general paediatric wards from 1
st
 October 2007 to 
31
st
 December 2007 were eligible for inclusion in the study.  There were two populations 
of interest, firstly the larger population of all children admitted to CHBH during the study 
period (used to calculate period HIV prevalence) and secondly, the HIV-infected paediatric 
population – which was a sub-sample of the larger population of all children admitted 
during the study period. 
 
The three month study period was chosen for several reasons: 
1. A convenience sample was selected in order to describe a recent cohort of 
consecutive HIV-infected inpatients. 
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2. A recent sample would allow calculation of period prevalence so that 
recommendations could be made based on current practice.   
3. Data was captured from a single paediatric registrar rotation period (October – 
January) giving greater consistency in hospital admission notes. 
4. The study investigator wanted to ensure a yield of at least 300 records of HIV-
infected children and (based on past admission statistics) estimated that at 
least 3 month‟s data was required to achieve that number. 
5. The number of children admitted and the mortality rate during this period was 
not very different from other quarters in the same year. 
  
Study methods and sampling 
To define the first study population of interest, the study investigator obtained the patient 
admission lists (with names and hospital numbers) for the study period from the 
comprehensive register of all paediatric admissions located in the acute admission ward 
(ward 36A.) All children being admitted pass through this ward before being transferred to 
one of the four general paediatric wards.  This data was checked against the intake list of 
admissions from each ward from 1 October to 31 December 2007. The list of names and 
hospital numbers was used to identify and locate the laboratory data for every child 
admitted during the study period. The NHLS laboratory-linked computerised results 
programme was searched to identify the HIV status of each child admitted during this study 
period.         
 
If no confirmatory HIV test result appeared in the laboratory results for the current or prior 
admissions to CHBH, then the study investigator attempted to obtain the child‟s hospital 
record.  The hospital record was then consulted to check if a confirmed HIV test result 
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from current or previous visits was documented in the medical notes and results flow chart.   
If no evidence of HIV testing could be found in the laboratory results or medical notes, 
then the HIV status was recorded as HIV-unknown. If the hospital file could not be located 
(this occurred in less than 20 cases) then the status remained classified as HIV-unknown. 
 
HIV-exposure at the outset was determined from laboratory results by either a reactive 
maternal HIV Elisa or a reactive HIV Elisa in a child less than 18 months old.  Thereafter, 
review of the hospital record for all HIV-unknown and HIV-exposed children was 
performed looking for documentation of HIV-infected maternal status in the hospital 
admission notes.  If maternal status was HIV-infected and child had no HIV PCR result, 
then the child‟s status was classified as HIV-exposed. If maternal status was unknown or 
negative and the child had no HIV test result, then the child‟s status was classified as HIV-
unknown. Thus the HIV prevalence was calculated using both laboratory data and hospital 
record review.    
 
All HIV test results accessed retrospectively for the study were processed by the NHLS as 
part of the routine laboratory service and were therefore subject to a standardized NHLS 
protocol for laboratory testing of HIV status. 
 
To define the second population of interest, the study investigator obtained the hospital 
records of all confirmed HIV-infected children (confirmed using the procedures described 
above) from the records department and then captured selected data on a standardized study 
tool by the study investigator (see Appendix 1.) Hospital records for HIV-negative, HIV-
unknown and HIV-exposed children were not analysed further, apart from the initial 
determination of HIV status (if no HIV test result had been found on laboratory search.) 
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because the main aim of the study was to describe period HIV prevalence, and then to 
describe disease profile and outcome amongst HIV-infected children.  Although 
comparison group/s (i.e. HIV-negative/HIV-exposed) would have been useful, the study 
investigator chose to focus only on confirmed HIV-infected children in order to determine 
access to, coverage and impact of the antiretroviral programme amongst a group of HIV-
infected inpatients. However, further studies would be helpful in assessing missed 
opportunities for PMTCT interventions and HIV screening amongst the larger group of 
paediatric inpatients.  Furthermore, a restricted study population was chosen due to funding 
and time constraints. 
 
Data regarding deaths among the HIV-infected group were obtained from hospital record 
review.  However, mortality data for the HIV-negative, HIV-unknown and HIV-exposed 
groups (admitted during the study period) was collected from the monthly morbidity and 
mortality reports for each of the four general paediatric wards at CHBH. 
 
 
2.2.1 Inclusion and exclusion criteria 
All children (from birth to 14 years of age) who presented to CHBH acute (general 
medical) paediatric admission ward between 1
st
 October 2007 and 31
st
 December 2007 
were included in the study sampling frame to determine HIV prevalence.  Only those 
children who had a documented positive HIV status (laboratory or hospital record) were 
included in the analysis of disease profile amongst HIV-infected children.   
 
All HIV-negative, HIV-exposed children (where no final HIV status could be determined 
from the hospital and laboratory records) and children of unknown HIV status were 
excluded from the second part of the study that described disease profile amongst 
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confirmed HIV-infected children.  The six HIV-infected children who were identified using 
the computerized laboratory record system but whose hospital records could not be located 
were included in the prevalence calculations but were excluded from all other study 
analyses. 
 
2.3 Materials and Data collection 
A pilot study was performed to assess the accessibility of records and the feasibility of 
collecting the required data on a pro-forma standardized study tool. (Appendix 1)  Based on 
the results of this pilot and on the advice of the postgraduate committee reviewing the 
protocol, some detailed data on the socio-demographics and clinical history of each child 
was omitted from the final data collection. This data included information on feeding 
history, maternal CD4 cell count, paternal and sibling HIV status, immunization record, 
area of residence, presenting symptoms, household income and social grant uptake. This 
data collection tool is explained in greater detail below. 
 
Although a computerised database of paediatric admission records exists, the data is 
incomplete since many of the paper copies of hospital discharge summaries have not been 
submitted for data capturing. Thus the only way to obtain complete data for the children 
identified as HIV-infected was to physically locate each hospital file in the CHBH Records 
Department. The study investigator (researcher) visited the CHBH Records Department 
and physically obtained all hospital records for children with unknown HIV status (to 
confirm that status was truly unknown) and for all HIV-infected children (as confirmed by 
hospital records). The researcher personally reviewed all data of interest and captured data 
on a standardized study tool. (Appendix 1)   The study tool was developed after a pilot 
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study to ensure ease of data extraction, coding for simplified analysis and gathered mainly 
closed-ended quantitative data.  
 
The following information was collected (where available from the hospital record) for 
each HIV-infected child: 
 Demographics: age in months (Ethics committee would not allow recording of date of 
birth) and gender 
 HIV testing ( whether newly-diagnosed in this admission) 
 PMTCT Details: self-reported HIV status of the biological mother, NVP prophylaxis to 
mother in labour and/or child at birth, place of birth 
 ART treatment history: Current treatment, need for ART, duration of ART, usage of 
CTX prophylaxis at time of admission. 
 Growth parameters: weight, height and Wellcome classification1 
 HIV Staging: WHO stage and clinical criteria for staging 
 
 Immunological indices: CD4 count and CD4 percentage 
 Primary diagnoses or reason for hospital admission: one primary and two secondary 
diagnoses could be recorded  
 Infectious pathogens: microbiology culture results and organisms identified via post-
mortem biopsy results could be recorded 
 Clinical outcome: discharged home – no ICU admission, discharged home after ICU 
admission, died in ICU, died in ward, transferred back to referring hospital, transferred 
to step-down hospital facility 
 Duration of hospital stay 
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2.4 HIV testing/HIV status 
As this was a retrospective study, laboratory and hospital records, as explained above, were 
used to determine HIV status.  HIV infection status was documented based on the NHLS 
laboratory system test result (using either a positive HIV-DNA polymerase chain reaction 
test (PCR) in children < 18 months or a positive HIV enzyme-linked immunosorbent assay 
(ELISA) in children > 18 months of age).  The NHLS laboratory records database 
contained records of all paediatric HIV PCR and HIV Elisa tests done at CHBH for at least 
the preceding 5 years.  The NHLS uses routine, standardised protocols in laboratory testing 
of HIV PCR and HIV Elisa specimens. 
  
In cases where no laboratory testing results were available, hospital records were obtained 
and HIV results documented therein were used to classify HIV status.  The clinicians 
documenting these results would have considered a positive virological test in children < 
18 months old or a positive antibody test in children ≥18 months old as proof of HIV 
infection.  This interpretation of HIV test results is in accordance with the National 
Department of Health‟s Guidelines 2005 guidelines for HIV testing of infants and children. 
32
 
 
2.5 Reference classifications  
Wellcome classification: This classification developed by the Wellcome Trust International 
Working Party on childhood malnutrition was utilised for categorization of nutritional 
status of HIV-infected children in this study.
1
 
 
WHO Clinical staging: (see Appendix 2) This staging system can be used for all children 
aged under 15 years with confirmed laboratory evidence of HIV infection. The revised 
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2004 version (as it appears in the “Guidelines for the management of HIV-infected 
children” was utilised for classification of children in this study.2  
 
WHO growth references: This study utilised the 2006 WHO standards for assessing the 
growth and development of children from birth to 5 years of age.
3, 4
 
 
2.6 Case definitions 
Pneumocytsis jiroveci pneumonia (PJP): A working clinical diagnosis of PJP at CHBH was 
considered in HIV-infected infants who fulfilled two or more of the following criteria: 
oxygen saturations less than 90% on admission or if ventilated, requirement of FiO2 >0.4 
for 4 or more consecutive days plus a respiratory rate > 60/minute, minimal findings on 
chest auscultation and a reticulonodular infiltrate on chest radiograph. These criteria are 
based on local teaching and the WHO clinical case definition of PJP.
5
 
 
Pulmonary Tuberculosis (pTB): A working clinical diagnosis of pTB at CHBH was 
considered in HIV-infected infants and children who fulfilled at least 2 of the following 
criteria: persistent cough for more than 2 weeks and/or fever for more than 1 week and/or 
recent failure to thrive, a history of a current TB contact, a positive tuberculin skin test 
(defined as induration > or equal to 5mm) and a suggestive chest radiograph or persistent 
infiltrates or lymphadenopathy on serial chest radiographs. 
  
Immune reconstitution inflammatory syndrome (IRIS): A working clinical diagnosis of 
IRIS at CHBH was considered in HIV-infected infants and children who fulfilled the IRIS 
case definition recommended in the “Guidelines for the management of HIV-infected 
children”: a paradoxical clinical deterioration within 6 weeks of starting ART, with new 
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symptomatic infection with pathogens reported to be associated with IRIS, particularly 
Mycobacterium tuberculosis, Mycobacterium avium complex , Mycobacterium bovis (BCG 
reactions) and Cytomegalovirus (CMV) infections amongst others.
2
 
 
2.7 Statistical analysis plan 
2.7.1 Determination of HIV prevalence  
 The total number of paediatric admissions over the study period 1 October to 31 December 
2007 was identified from the hospital admission register and ward admission records. 
Laboratory results and hospital folder search was performed in order to determine HIV 
status. Crude HIV prevalence was calculated using the formula: crude period prevalence = 
total HIV-infected admissions / total admissions. The total number of HIV-infected 
children (446) was used for the prevalence calculations, whereas for the secondary analyses 
(see below), data was only available for 440/446 HIV-infected children. The same formula 
was used to calculate the crude period prevalence of HIV-negative, HIV-exposed and HIV-
unknown status.  The 95% confidence interval was calculated using statistical software, 
SAS version 9.1 (SAS Institute Inc., Cary NC, USA).
40
 
          
2.7.2 Data entry and management for the HIV-infected sub-population 
Four hundred and forty hospital files in the CHBH records department were analysed.      
The study investigator entered data into EpiData v3.1.
41
    Data quality was checked by 
performing frequencies on categorical variables such as HIV status and by checking the 
range of continuous variables such as age and weight.   The study investigator exported 
data to SAS version 9.1 (SAS Institute Inc., Cary NC, USA) for further quantitative 
analysis.
40
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2.7.3 Statistical Methods 
 Data was analysed and described by calculating frequencies, means, medians and standard 
deviations (for parametric data) and median values and interquartile range or ranges (for 
non-parametric data).  Where groups were compared, student t-tests were used for 
continuous variables with normal distribution and Wilcoxon-Rank Sum tests were used for 
non-normally distributed data. Pearson chi-squared test was used to determine the 
association between non-ordinal categorical data; where expected cell count was less than 5 
Fischer exact test was used to determine association between groups. A p-value of < 0.05 
was considered to be statistically significant. 
 
2.7.4 Analysis describing the study population 
Data for the 440 HIV-infected children was subdivided into four age categories for analysis 
PMTCT interventions in infants aged less than 6 months, immunological indices by age, 
breakdown of deaths by age and calculation of case fatality rates by age group. Frequency 
calculation was done to determine what proportion of the study population was newly-
diagnosed and what proportion was known to be HIV-infected at the time of hospital 
admission.  The study population was then assigned a Wellcome classification and the 
frequency of each weight category eg. marasmic, was calculated.  Weight for age z-scores 
were calculated for age categories less than 60 months of age using a macro on SAS based 
on WHO references.
3
  Frequency calculations were performed for WHO HIV staging, 
staging criteria, ART status, primary diagnosis, spectrum of infectious pathogens, and 
cause of death analyses. Median and interquartile (25
th
 – 75th) ranges were calculated for 
immunological indices.  
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2.7.5 PMTCT Sub-analysis 
Data concerning PMTCT interventions was analysed for a subgroup of the study 
population, namely the age category of HIV-infected infants less than 6 months old.  
Frequency calculations were performed for maternal HIV status, NVP exposure, CTX 
prophylaxis and place of birth. The uptake of PMTCT interventions was then compared by 
maternal HIV status grouping using the Pearson chi-squared test.  Frequency calculation 
was performed to breakdown uptake of PMTCT interventions in infants less than 6 months 
of age.  
 
2.7.6 Determination of Case fatality rates 
The total number of deaths in the HIV-negative, HIV-unknown and HIV-exposed group 
was divided by the total number of admissions for each group over the same study period 
to obtain the case fatality rate data.  Case fatality rates were also calculated by age category 
for HIV-infected children. .  The 95% confidence interval was calculated using statistical 
software, SAS version 9.1 (SAS Institute Inc., Cary NC, USA).
40
 
 
2.7.7 Comparison of HIV-infected patient characteristics by final outcome 
Children who survived were compared with children who died, for variables such as age, 
weight for age z-score, median CD4 count, ART status, WHO HIV stage, CTX prophylaxis 
uptake and timing of HIV diagnosis. Pearson chi-squared tests were used for categorical 
data (Fischer exact test if expected cell count<5) , student t-tests for parametric continuous 
data, and Wilcoxon rank sum test for non-parametric continuous data.   
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2.7.8 Comparison of HIV-infected patient characteristics by ART status 
Children receiving ART were compared to ART-naive children for variables such as age, 
weight for age z-score, median CD4 count, duration of hospital stay, WHO HIV stage, 
CTX prophylaxis uptake and inpatient mortality rate.  Pearson chi-squared tests were used 
for categorical data (Fisher exact test if expected cell count<5), student t-tests for 
parametric continuous data, and Wilcoxon rank sum test for non-parametric continuous 
data.   
 
2.8 Ethics clearance 
The study was approved by the University of the Witwatersrand Human Research Ethics 
Committee (reference no. M080202).  Permission was obtained from the hospital 
administration to perform a retrospective review of hospital records.  (see Appendix 3) 
 
The protocol was also presented to the paediatric post-graduate committee. The latter 
recommended that the student limit the scope of this work, and subsequently approved the 
current protocol and focus as adequate for the MMed thesis. 
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3. R 3. Results  
 
 
 
 
     
Figure 1.  Schematic overview of the study population 
The flow diagram in Figure 1. demonstrates how HIV status was determined for all 1510 
children admitted to the paediatric wards between 1
st
 October and 31
st
 December 2008.  
The study population included all children identified to be HIV-infected after review of 
laboratory and hospital records.  Six HIV-infected children whose hospital records could 
not be located were excluded from all further analyses after HIV prevalence had been 
calculated. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             
1510 general paediatric admissions between 1
st
 October – 31st December 2007 
 
1510 hospital number NHLS computer searches performed 
HIV-negative 
 
(negative HIV PCR if 
<18 mo. or negative 
Elisa test if > 18mo.) 
 
n = 780 
(51.7%) 
HIV-infected 
 
(positive HIV PCR if 
<18 mo. or positive 
Elisa test if > 18mo.) 
 
n = 446 
(29.5%) 
HIV-exposed 
 
(mother HIV-infected 
but no confirmatory 
HIV PCR test result for 
infant)   
n = 57 
(3.8%) 
 
HIV-unknown 
 
(no confirmed  HIV 
status for mother or 
child from lab or 
hospital records) 
n = 227 
(15%) 
 
STUDY POPULATION: 
For the 446 HIV-infected children, 440 hospital files and/or discharge summaries were located 
and reviewed using the study tool for data capture. 
 
EXCLUSIONS: 
Hospital records could not be located for 6 of the 446 HIV-infected children. These children  
were included in the prevalence calculation but were excluded from all other study analyses. 
 
HIV test results of 1098 children were obtained from NHLS computer searches. 
 
For the remaining 412 children with no HIV test results on the NHLS computer search, 393 
hospital folders were located to determine if HIV status was documented in laboratory 
chart/medical notes from the current / previous admissions.  
 
Based on these search results, 1510 children were classified by HIV status: 
 
 
 
  24 
3.1 HIV prevalence 
A total of 1510 children were admitted to the four general paediatric wards over the three 
month study period.   Laboratory results from the NHLS data system were used to 
determine HIV status of paediatric inpatients admitted during the study period: The HIV 
status of 412 children was not documented in the NHLS database. Hospital records for 393 
of these children were located and examined to obtain HIV status. Of these 1510 children, 
446 (29.5% [95% CI 27.2-31.9]) were HIV-infected, 780 (51.7% [95% CI 49.1-54.2]) were 
HIV-negative, 57 (3.8% [95% CI 2.9-4.9]) were HIV-exposed and 227 (15% [95% CI 
13.3-16.9]) were of unknown HIV status (see Table 1).  HIV prevalence amongst paediatric 
admissions during the study period may have been higher than 29.5%, since some of the 
HIV-exposed infants and children of unknown HIV status may have been HIV-infected. 
 
 
Table 1.  HIV prevalence amongst paediatric admissions at CHBH 
HIV Status 
 
Number admitted 
n = 1510 
Percentage prevalence 
Total = 100% 
95% Confidence 
Interval 
HIV-infected 446 29.5 27.2 – 31.9 
HIV-negative 780 51.7 49.1 – 54.2 
HIV-exposed 57 3.8 2.9 – 4.9 
HIV-unknown 227 15 13.3 – 16.9 
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3.2 Characteristics and disease profile of confirmed HIV-infected paediatric 
admissions 
3.2.1 Demographics 
Four hundred and forty-six HIV-infected children were admitted during the study period.  
Six hospital records from the study sample of 446 HIV-infected children could not be 
located and these children were thus excluded from the study.  Of the remaining 440 
children, 234 (53.2%) were male and 206 (46.8%) were female.  Their ages ranged from  
1 month to 167 months with a median age of 10 months and an interquartile (IQR) [25
th
 to 
75
th
 quartiles] range of 3 to 44.5 months.   No other socio-demographical data was 
collected for these children.  The age distribution of the 440 HIV-infected children was: 
166 (37.7%) under 6 months of age, 116 (26.4%) 6 to 23 months of age, 60 (13.6%) 24 to 
59 months of age and 98 (22.3%) over 60 months of age. 
The age distribution of HIV-infected children is illustrated in Figure 2. 
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Figure 2. Age distribution of 440 HIV-infected paediatric 
admissions by age category 
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3.2.2 Timing of HIV diagnosis amongst HIV-infected children 
Of the 440 children in the study population, 238 (54.1%) were newly diagnosed with HIV 
during ward admission.  Two hundred and two children (45.9%) were known to be HIV-
infected (of which more than 90% were currently attending hospital or community-based 
HIV clinics, although data on the breakdown of different HIV services attended was not 
formally collected.)   The newly diagnosed children were more likely to be younger 
(median age of 6 months) whereas children known to be HIV-infected were older (median 
age of 20 months.) (p = 0.001) Data regarding timing and place of HIV diagnosis in the 
group known to be HIV-infected were not available from hospital records.  
 
3.2.3 Self reported access to prevention of mother-to-child transmission (PMTCT) 
services amongst HIV-infected children less than 6 months of age 
Data concerning PMTCT interventions was analysed for a subgroup of the study 
population, namely HIV-infected infants under the age of 6 months (n=166).  Owing to the 
limited availability of data, review of PMTCT interventions was restricted to HIV-infected 
infants under 6 months of age, who were more likely to have PMTCT data recorded in their 
files. Self-reported maternal HIV status, Nevirapine (NVP) exposure and use of 
Cotrimoxazole (CTX) prophylaxis were determined for this subgroup.   
 
3.2.3.1 Self reported maternal HIV status  
Ninety of 166 (54.2%) mothers to HIV-infected infants less than 6 months old reported 
their status as HIV-positive and 25/166 (15.1%) reported their status as HIV-negative.   
A further 51/166 (30.7%) mothers reported their status as HIV-unknown or -untested or 
had no data regarding maternal HIV status available in their infant‟s hospital record.  The 
latter group of HIV-infected infants whose mothers‟ HIV status was unknown included 
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abandoned infants, maternal orphans and infants brought to hospital by a caregiver other 
than the biological mother.   
 
Of the 25 mothers reporting their status as HIV-negative, 13/25 (52%) had delivered at 
CHBH, 5/25 (20%) at a clinic, 3/25 (12%) at another hospital, 1/25 (4%) was born before 
arrival at hospital (BBA) and in 3/25 (12%) birthplace could not be determined from the 
hospital record. HIV was newly diagnosed in 22/25 (88%) of infants to these mothers (who 
reported their status as HIV-negative).     
 
3.2.3.2 Nevirapine exposure 
The frequency of NVP exposure as part of the PMTCT programme was calculated for this 
subgroup of HIV-infected infants less than 6 months of age.  Sixty of 166 (36.2%) 
mother/infant pairs received NVP, 55/166 (33.1%) did not receive NVP and in 51/166 
(30.7%) it could not be determined if NVP was received as either the required data had not 
been recorded or was unknown to the mother.  In the latter (NVP unknown) group, the 
majority of cases had no PMTCT information recorded in the hospital file and a minority 
had documented in their hospital record that the primary caregiver or mother was unsure if 
NVP had been received. 
 
3.2.3.3 Cotrimoxazole prophylaxis 
Frequency of CTX prophylaxis usage at the time of hospital admission was determined by 
review of admission records for the subgroup of HIV-infected infants under 6 months of 
age.  Forty-six of 166 (27.7%) infants were currently receiving CTX, 114/166 (68.7%) 
were not currently receiving CTX and in 6/166 (3.6%) infants CTX usage was unknown.  
Those infants that had received NVP at birth were significantly more likely to be receiving 
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CTX at the time of hospital admission, compared with infants who had not received NVP 
or had unknown NVP exposure. (p=0.008)   
 
The 114/166 (68.7%) infants who were not receiving CTX prophylaxis at the time of 
hospital admission included 34 infants under the age of 2 months. As per a request from the 
Wits Ethics committee, age in months rather than exact date of birth was documented 
during data collection.  Therefore it was not possible to calculate exactly how many infants 
were less than 6 weeks of age and therefore not yet commenced on CTX prophylaxis at the 
time of hospital admission.  If these 34 infants under the age of 2 months are excluded from 
the analysis i.e. 166 - 34 = 132, then 40/132 (30.3%) infants were currently receiving CTX, 
86/132 (65.2%) were not currently receiving CTX and in 6/132 (4.5%) infants CTX usage 
was unknown.    
 
Among the same overall subgroup of infants (n = 166), 51/166 (30.7%) were known to be 
HIV-infected and 115/166 (69.3%) were newly diagnosed at the time of hospital 
admission.  Of the 51 infants previously diagnosed/known to be HIV-infected, 39/51 
(76.5%) were receiving CTX prophylaxis at the time of hospital admission.  Among the 
115 newly diagnosed infants, 7/115 (6.1%) were receiving CTX prophylaxis.  The 7 infants 
newly diagnosed but already receiving CTX, were infants who were known to be HIV-
exposed at birth. They had been correctly commenced on CTX prophylaxis from 6 weeks 
of age, but had not had HIV PCR testing before hospital admission.  
 
Table 2. indicates the breakdown of PMTCT interventions amongst the subgroup of infants 
less than 6 months of age. (n = 166) 
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Table 2. Breakdown of PMTCT interventions in infants less than 6 months of age  
PMTCT intervention/s Frequency/Number 
(Total n = 166) 
Percentage 
(Total = 100%) 
No interventions 76 45.8 
NVP + CTX + early diagnosis  20 12 
NVP + CTX  4 2.4 
NVP + early diagnosis 4 2.4 
CTX + early diagnosis 19 11.5 
NVP only 32 19.3 
CTX only 3 1.8 
Early diagnosis only 8 4.8 
 
Seventy-six (45.8%) of all 166 infants less than 6 months of age received no PMTCT 
interventions. Only 20/166 (12%) of infants received all recommended interventions i.e. 
NVP and CTX prophylaxis and an early HIV PCR test to diagnose HIV infection. 
 
3.2.3.4 Place of birth 
Table 3. displays data on place of birth for the subgroup of HIV-infected infants less than 6 
months old. Eighty-three of 166 (50.1%) infants were born at CHBH, 21/166 (12.6%) at a 
local clinic, 20/166 (12.0%) at another hospital, 4/166 (2.4%) at home/BBA and 38/166 
(22.9%) of unknown birthplace.   There was no statistically significant association between 
place of birth (CHBH versus clinic/other hospital/BBA) and access to NVP or CTX. (p = 
0.1288 and p = 0.5818 respectively.) 
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Table 3. PMTCT interventions in infants less than 6 months of age by place of birth 
Place of Birth Number of infants 
n = 166 
(100%) 
Received NVP 
  
(%) 
Received CTX 
  
(%) 
 
CHBH 83 
(50.1) 
43/83 
(51.8) 
26/83 
(31.3) 
Clinic 21 
(12.6) 
6/21 
(28.6) 
4/21 
(19) 
Other hospital 20 
(12) 
9/20 
(45) 
7/20 
(35) 
BBA 4 
(2.4) 
2/4 
(50) 
1/4 
(25) 
Birthplace Unknown 38 
(22.9) 
0/38 
(0) 
8/38 
(21) 
 
All infants 
< 6 months of age 
166 
(100) 
60/166 
(36.2) 
46/166 
(27.7) 
 
 
Data for NVP and CTX use was stratified and re-analysed by place of birth at local clinic 
and at other hospitals.  When comparing infants born at CHBH versus birth at a clinic, the 
difference in documented NVP use approached statistical significance (p = 0.057) 
However, there was no difference in frequency of NVP usage between infants born at 
CHBH versus infants born at other hospitals (p = 0.5847). There was also no statistically 
significant association between place of birth and CTX usage when stratified for CHBH 
versus local clinic and CHBH versus other hospitals (p = 0.2672 and p = 0.7519 
respectively.) 
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3.2.3.5 PMTCT interventions by maternal self-reported HIV status 
Table 4. Comparison of NVP and CTX prophylaxis uptake in infants less than 6 
months of age by self-reported maternal HIV status 
 
 
 
 
 
 
 
PMTCT 
intervention 
Self-reported HIV status of mothers to infants  < 6 mo. 
(n=166) 
Total 
(regardless of 
maternal HIV 
status) 
 
n = 166 
(100%) 
Mother 
reportedly 
HIV-positive 
 
 
n = 90 
(54.2%) 
Mother 
reportedly HIV 
-negative or  
HIV-unknown 
 
n = 76 
(35.8%) 
 
 
 
 
 
 
p-value 
 
Mother/infant  
pair received NVP 
Yes 
No 
Unknown 
 
 
60 (36.2) 
55 (33.1) 
51 (30.7) 
 
 
60 (66.7) 
13 (14.4) 
17 (18.9) 
 
 
0 (0) 
42 (55.2) 
34 (44.8) 
 
 
 
 
<0.0001 
 
Infant receiving  
CTX prophylaxis 
Yes 
No  
Unknown 
 
 
46 (27.7) 
114 (68.7) 
6 (3.6) 
 
 
35 (38.9) 
50 (55.6) 
5 (5.5) 
 
 
11 (14.5) 
64 (84.2) 
1 (1.3) 
 
 
 
 
0.0001 
 
Table 4. compares uptake of NVP and CTX prophylaxis among infants less than 6-months 
whose mothers were reportedly HIV-positive versus mothers reportedly HIV-negative or 
HIV-unknown.  Infants whose mothers reported their status as HIV-positive were 
significantly more likely to have received NVP and CTX prophylaxis than infants whose 
mothers reported their status as HIV-negative or HIV-unknown. (p = <0.0001 and 0.0001 
respectively) 
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3.2.3.6 Missed opportunities for PMTCT interventions 
The flow chart below highlights the multiple levels of missed opportunities for PMTCT 
implementation in the subgroup of infants under 6 months of age whose mothers reported 
their status as HIV-positive. 
 
Figure 3. Missed opportunities for PMTCT interventions in infants less than 6 months 
old born to mothers who self-reported their status as HIV-positive 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proportion of mothers to HIV-infected infants  
< 6mo. old reporting their status as HIV-positive 
n = 90/166 (54.2%) 
 
Of these mothers (reportedly HIV-positive), proportion  
of mother/infant pairs NOT receiving NVP prophylaxis 
n =30/90 (33.3%) 
 
Of infants to these (reportedly HIV-positive) mothers, 
proportion of infants NOT receiving CTX prophylaxis 
n = 55/90 (61.1%) 
Of infants to these (reportedly HIV-positive) mothers, 
proportion of infants NOT receiving  
HIV PCR testing before hospital admission 
n = 53/90 (58.9%) 
Missed opportunity #1: 
 
NVP prophylaxis 
Missed opportunity #2: 
 
CTX prophylaxis 
 
Missed opportunity #3: 
 
Early HIV diagnosis 
 
Of the known HIV-infected infants (n = 37),  
proportion of infants NOT receiving ART  
at the time of hospital admission 
n = 25/37 (67.6%) 
 
Missed opportunity #4: 
 
Early ART initiation 
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The flow chart below highlights the multiple levels of missed opportunities for PMTCT 
implementation in the subgroup of infants under 6 months of age whose mothers reported 
their status as HIV-negative or HIV-unknown. 
 
Figure 4. Missed opportunities for PMTCT interventions in infants less than 6 months 
old born to mothers who self-reported their status as HIV-negative or HIV-unknown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proportion of mothers to HIV-infected infants  
< 6mo. old reporting their status as  
HIV-negative or HIV-unknown 
n =76/166 (45.8%) 
Of these mothers (reportedly HIV-negative/-unknown), 
proportion of mother/infant pairs  
NOT receiving NVP prophylaxis.        
n =76/76 (100%) 
Of infants to these (reportedly HIV-negative/-unknown) 
mothers, proportion of infants  
NOT receiving CTX prophylaxis 
n = 65/76 (85.5%) 
Of infants to these (reportedly HIV-negative/-unknown) 
mothers, proportion of infants NOT receiving  
HIV PCR testing before hospital admission 
n = 61/76 (80.3%) 
Missed opportunity #1: 
 
Antenatal VCT 
Missed opportunity #2: 
 
NVP prophylaxis 
Missed opportunity #3: 
 
CTX prophylaxis 
 
Missed opportunity #4: 
 
Early HIV diagnosis 
 
Of the known HIV-infected infants (n = 37),  
proportion of infants NOT receiving ART  
at the time of hospital admission 
n = 13/15 (86.7%) 
 
Missed opportunity #5: 
 
Early ART initiation 
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No detailed data was collected on whether mothers were actually tested for HIV, when they 
were tested and why in many cases, mothers with HIV-infected infants reported their own 
status as HIV-negative or HIV-unknown. This information, although interesting and important, 
was not available from the hospital records and was beyond the scope of the thesis. 
 
3.2.4 Nutritional status 
Of the 440 records found for HIV-infected children admitted during the study period, 9 
records had no documentation of weight at the time of hospital admission and therefore 
n=431.  For these 431 children, nutritional status was assessed using the Wellcome 
classification.  
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Figure 5. Wellcome classification of HIV-infected children 
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The majority (80.8%) of children were malnourished when assessed using the Wellcome 
classification.  Only 19.2% of children had a normal weight for age (above the 3
rd
 centile 
for expected weight for age on the WHO growth reference charts.)   
 
Table 5. Median weight for age z-scores by age category in months 
Age category Number of children Median weight for age 
 z-score 
< 6 months 163 -3.52 
6 – 23 months 116 -3.29 
24 – 60 68 -1.93 
All children 60 months or less 347* -3.23 
*Total number of children aged 60 months or less for whom admission weight data was available. 
 
Table 5. describes weight for age z-scores analysed for a subgroup of the study population 
who were 60 months or less of age and who had admission weight data recorded in the 
hospital file. (n = 347)  Analysis was performed using WHO references that are only 
available for children 60 months of age or younger.  Therefore no weight for age z-score 
analyses were performed for children above 60 months of age. The median weight for age 
z-score in children 60 months and younger was -3.23, with an interquartile (25
th
 to 75
th
 
quartiles) range of -4.3 to -1.71.  Older children (between 24 and 60 months of age) had a 
better, although still decreased median weight for age z-score of -1.93.   
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3.2.5 HIV staging 
WHO HIV staging classification (Appendix 2) was determined by review of clinical 
parameters documented in the hospital record from the time of hospital admission.  Almost 
93% of all paediatric admissions had advanced HIV disease and were classified as WHO 
HIV stage 3 or 4. 
 
Table 6.  WHO Staging of 440 HIV-infected paediatric admissions at CHBH 
WHO HIV Stage Number (n = 440) Percent (100%) 
1 3 0.7 
2 29 6.6 
3 188 42.7 
4 220 50 
 
 
Table 7. documents the breakdown of criteria used to classify the 440 HIV-infected 
children by WHO HIV stage.  On Wellcome classification, 348/431 children who had 
admission weight data available were malnourished.  The number of children in whom 
failure to thrive (FTT) was used as a WHO HIV staging criterion is discrepant with the 
number of malnourished children (by Wellcome classification) because criteria other than 
FTT were used in many cases to assign WHO HIV stage.*  Other than FTT, pulmonary TB 
and presumed HIV encephalopathy were the most common staging criteria used. 
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Table 7. Prevalence of specific WHO staging criteria amongst 440 HIV-infected 
paediatric admissions at CHBH 
Staging Criteria Number (n=440) Percent (100%) 
Stage 1:  
Generalized lymphadenopathy 
 
3 
 
0.7 
Stage 2:  
Severe bacterial infection 
 
6 
 
1.4 
Hepatosplenomegaly 23 5.2 
Stage 3**:  
Pulmonary TB 
 
74 
 
16.8 
Moderate FTT (60-80% expected weight for age) 105* 23.9 
Stage 4**:  
Extrapulmonary TB 
 
26 
 
5.9 
Severe FTT (< 60% expected weight for age) 102* 23.2 
Presumed HIV encephalopathy 40 9.1 
Severe FTT + encephalopathy 21 4.8 
Pneumocystis jiroveci pneumonia 18 4.1 
Cytomegalovirus infection 5 1.1 
Other
#
  18 3.4 
#
 cytopaenias, oesophageal candidiasis, HIVAN, NHL, disseminated MAC, recurrent pneumonia.  
* The number of children in whom failure to thrive (FTT) was used as a WHO HIV staging criterion is 
discrepant with the number of malnourished children (by Wellcome classification) because criteria other than 
FTT were used in many cases to assign WHO HIV stage. 
** The difference between number and percentage of children with stage 3 and stage 4 criteria in Table 6. is 
made up by children with WHO HIV staging criteria shown in the category “Other”. 
 
 3.2.6 Antiretroviral treatment (ART) 
Of the 440 HIV-infected children in the study population, 76 (17.3%) were on ART and 
364 (82.7%) were not currently on ART at the time of hospital admission. Of the 76 
(17.3%) children receiving ART at the time of hospital admission, the median duration of 
treatment was 2 months, with an interquartile (25
th
 to 75
th
 quartile) range of 1 to 10 months 
and a minimum of 1 and maximum of 48 months. Of the 364 children not currently on 
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ART at the time of hospital admission, 345/364 (94.7%) had never been on ART, 4/364 
(1.1%) had been previously treated but had stopped therapy and 15/364 (4.1%) had ART 
initiated as an inpatient during the course of their admission.   
 
Of the 364 (82.7%) children not receiving ART at the time of hospital admission, 346 
(95%) qualified for HAART. This calculation was based on the 2004 South African 
National Antiretroviral Treatment Guidelines for paediatric patients.
2
  These guidelines 
recommended ART initiation in children less than 18 months of age with WHO stage 3 or 
4 disease and/or CD4 < 20% and for children 18 months or older recommended ART 
initiation with WHO stage 3 or 4 disease and/or CD4 < 15%.  There are other clinical 
(recurrent or prolonged hospitalisation) and social (identifiable caregiver and HIV 
disclosure) criteria for paediatric ART initiation which were not taken into account for this 
calculation owing to the lack of relevant information in hospital admission notes. 
 
Of the 202/440 (45.9%) children known to be HIV-infected before hospital admission, 
74/202 (36.6%) were currently receiving ART. Of the remaining 128/202 children known 
to be HIV-infected before hospital admission, 121/128 (94.5%) had WHO HIV stage 3 or 4 
disease and thus were eligible for ART. 
 
The flow chart in Figure 6.below illustrates the uptake of antiretroviral treatment amongst 
the 440 HIV-infected children in the study population.  
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Figure 6. Antiretroviral treatment status among 440 HIV-infected children 
 
*Eligibility was determined during data analysis and was based on the criteria stipulated in 
the 2004 South African National Antiretroviral Treatment Guidelines for paediatric 
patients.
2
   
 
3.2.7 Immunological indices  
CD4 percentages and absolute CD4 counts were analysed in a subgroup of the study 
population who had CD4 testing performed within a month before or after the date of 
hospital admission.  This subgroup was selected so that only CD4 counts from a timeframe 
close to that of the hospital admission date were analysed. The median CD4 percentage was 
15% (IQR 18.2- 22.8) for the 320 children in whom recent results were available. Two 
hundred and fifty-four (79.4%) of the group had CD4 percentages of <25%, indicative of 
immune suppression. The median CD4 cell count was 485 cells/ul (IQR 192 - 932) for the 
Study population of HIV-infected children 
n = 440 (100%) 
 
Current ART 
n = 76/440  
(17.3%) 
 
Not on ART at time of hospital admission 
n = 364/440  
(82.7%) 
Previous ART 
n = 4/440 
 (0.9%) 
 
ART initiated during 
current hospitalisation 
n = 15/440 
(3.4%) 
 
ART-naive 
n = 345/440  
(78.4%) 
 
Total eligible for ART / Total not on ART  
at the time of hospital admission* 
n = 346/364 (95.0%) 
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312 children in whom recent results were available. One hundred and sixty (51.3%) of the 
group had CD4 cell counts of <500 cells/ul, indicative of immune suppression. 
 
Table 8.  Median CD4 percentages classified by age group in months and proportion 
of CD4 percentages less than 25%  
         
All age categories combined 
(n = 320)* 
 
<6mo 
(n = 116) 
 
6-23mo 
(n = 73) 
 
24-59mo 
(n = 46) 
 
>= 60mo 
(n = 85) 
Median CD4 
percentage 
(IQR) 
 
15.0% 
(18.2- 22.8) 
 
19.8% 
 (13.7- 28.5) 
 
15.9% 
(11.5 - 22.6) 
 
12.6% 
(6.6 - 19.4) 
 
8.0% 
(4.5 - 14.7) 
 
CD4% < 25%# 
(percentage) 
 
254/320 
(79.4) 
 
76/116 
(65.5) 
 
58/73 
(79.5) 
 
39/46 
(84.8) 
 
81/85 
(95.3) 
 
 
* Only 320/440 HIV-infected children had a CD4 percentage available that fell within the 
investigator-stipulated one month selection period on either side of the hospital admission 
date. # The CD4 percentage cut-off selected corresponds with the Centres for Disease 
Control (CDC) 1994 Revised Classification System for Human Immunodeficiency Virus 
Infection in Children Less Than 13 Years of Age which considered a CD4 percentage 
below 25% as evidence of immune suppression.
42
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Table 9.  Median CD4 count classified by age group in months and proportion of 
absolute CD4 counts < 500 cells/ul 
 
All age categories combined 
(n = 312)* 
<6mo 
(n = 113) 
6-23mo 
(n = 71) 
24-59mo 
(n = 45) 
>= 60mo 
(n = 83) 
Median CD4 cell 
count - cells/ul 
(IQR) 
 
485  
(192-932) 
 
796 
(377 - 1474) 
 
536 
(395 - 889) 
 
476 
(208 - 875) 
 
171 
(44 - 389) 
CD4 count  
< 500 cells/ul# 
(percentage) 
 
160/312 
(51.3) 
 
35/113 
(31.0) 
 
32/71 
(45.0) 
 
24/45 
(53.3) 
 
69/83 
(83.1) 
 
* Only 312/440 HIV-infected children had an absolute CD4 count available that fell within 
the investigator stipulated one month selection period on either side of the hospital 
admission date. # The absolute CD4 count cut-off selected corresponds with the Centres for 
Disease Control (CDC) 1994 Revised Classification System for Human Immunodeficiency 
Virus Infection in Children Less Than 13 Years of Age which considered a CD4 count 
below 500 cells/ul as evidence of moderate immune suppression in children aged 6 – 12 
years and as evidence of severe immunosuppression in children less than 5 years of age.
42
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3.2.8 Primary diagnosis  
The primary diagnoses or main reasons for hospitalisation of HIV-infected paediatric 
admissions at CHBH are summarised in Table 10. 
 
Table 10.  Primary Diagnoses 
Primary Diagnosis Number      
(n = 440) 
Percent      
(100%) 
Pneumonia - other than Pneumocystis jiroveci pneumonia (PJP) 
and pulmonary tuberculosis (pTB) 
125 28.4 
Gastroenteritis 77 17.5 
Pulmonary TB (pTB) - (45  presumed +  
10 confirmed cases) 
55 12.5 
Other*  49 11.1 
Septicaemia 42 9.6 
Extrapulmonary TB (EPTB) 30 6.8 
PJP/presumed PJP 24 5.5 
Meningitis 23 5.2 
Urinary Tract Infection 15 3.4 
*anaemia, chronic lung disease, Cor pulmonale, IRIS, HIVAN 
 
Pneumonia (other than PJP ad pTB) and gastroenteritis were the most frequent primary 
diagnoses at the time of hospital admission, accounting for 125/440 (28.45) and 77/440 
(17.5%) respectively.  Tuberculosis (pulmonary and extra-pulmonary) represented 55/440 
(12.5%) and 30/440 (6.8%) of all primary diagnoses. 
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In some of the 440 HIV-infected children, the admitting doctor had recorded more than one 
diagnosis. Based on the ranking of the diagnoses in the hospital records, a primary and 
secondary diagnosis was recorded during data collection. Data on the primary and 
secondary diagnoses (reasons for hospitalization) were combined to produce Figure 7. 
which illustrates the proportional contribution of the four main reasons for hospital 
admission: 
 Respiratory illness (including PJP and CMV pneumonitis) accounted for 37.5% of all 
admission diagnoses. 
 Tuberculosis (including pulmonary and EPTB) accounted for 21% of all admission   
diagnoses. 
 Gastroenteritis accounted for 22% of all admission diagnoses. 
 Sepsis (including septicaemia, meningitis and urinary tract infection) accounted for 
19.5% of all admission diagnoses. 
 
 
Figure 7. Principal  reasons for hospitalisation 
Respiratory illness  
37.5
% 
Tuberculosis 21% 
Gastroenteritis  
22% 
Sepsis 19.5% 
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3.2.9 Spectrum of infectious pathogens 
One hundred and ten children (25%) of the HIV-infected study population had a confirmed 
bacterial, viral, protozoal or fungal infection during their hospital admission.  The spectrum 
of pathogens that were encountered is represented in table 11.  Percentage representation of 
each pathogen was calculated for the bacterial organisms only. 
 
Table 11.  Spectrum of infectious pathogens (bacterial and other) 
Organism – Bacteria n = 86 Percentage of total 
bacterial pathogens 
Streptococcus pneumoniae 23 26.7 
E coli species 16 18.6 
Mycobacterium tuberculosis 10 11.6 
Salmonella species 6 7.0 
E coli extended spectrum B-lactamase producer 
(ESBL) 
4 4.7 
Klebsiella extended spectrum B-lactamase producer 
(ESBL) 
4 4.7 
Haemophilus influenza 3 3.5 
Klebsiella species 3 3.5 
Enterococcus faecalis 3 3.5 
Methicillin-resistant Staphylococcus aureus (MRSA) 3 3.5 
Acinetobacter baumanni 3 3.5 
Mycobacterium avium intracellulare  1 1.2 
Other bacterial:  Staphylococcus aureus, Proteus 
mirabilis, Pseudomonas aueruginosa, 
Enteropathogenic ecoli 
7 8 
Organism – Viral/Other n = 24  
Cytomegalovirus 14  
Varicella zoster 3  
Parvovirus 2  
Herpes zoster 2  
Measles 1  
Malaria falciparum 1  
Candida albicans 1  
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Streptococcus pneumoniae was the most common bacterial isolate and Cytomegalovirus 
was the most common viral isolate among the 440 HIV-infected children.  Of note was that 
many bacterial isolates from admission blood cultures were resistant to the empiric, first-
line antibiotic regimen (Ampicillin and Gentamicin) employed at CHBH to treat presumed 
bacterial infections in immunocompromised (HIV-infected) children.  Of all bacterial 
isolates (excluding M. tuberculosis and MAC) on blood, CSF and urine culture, 48% 
(36/75) were fully or intermediately resistant to one or both of these first line antibiotics. 
The proportion of isolates resistant to both antibiotics versus single antibiotic resistance 
was not recorded during the initial data collection and thus further analysis of resistance 
patterns is not possible with the existing dataset. 
 
Table 12.  Spectrum of infectious pathogens in the 53 HIV-infected children who died 
Organism  Number 
 
(n = 24) 
Percentage  
 
(100%) 
Streptococcus pneumoniae 5 20.8 
Cytomegalovirus 5 20.8 
E coli species 3 12.5 
Mycobacterium tuberculosis 3 12.5 
Klebsiella extended spectrum B-lactamase producer 
(ESBL) 
2 8.2 
Salmonella species 1 4.2 
E coli extended spectrum B-lactamase producer (ESBL) 1 4.2 
Proteus mirabilis 1 4.2 
Pseudomonas aueruginosa 1 4.2 
Klebsiella species 1 4.2 
Enterococcus faecalis 1 4.2 
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Table 12. lists the organisms cultured or proven on post-mortem biopsy specimens (in the 
case of CMV infection) among the 53 children who died.  Of these children, 24/53 (45.3%) 
had a culture-confirmed infection in blood, urine or CSF culture at the time of death. The 
remaining 29/53 children who died had no growth on blood cultures.   Children who died 
were significantly more likely to have a proven infection compared to children who 
survived (p=< 0.001).  In 5/53 (9.4%) children who died, Streptococcus pneumoniae was 
isolated on culture of blood or CSF.  In another 5/53 (9.4%) children who died, 
Cytomegalovirus infection was confirmed on post-mortem biopsy specimens. 
 
3.2.10 Outcome of HIV-infected paediatric admissions at CHBH 
Of the 440 HIV-infected children admitted during the study period, 309 (70.2%) were 
discharged home with no ICU stay, 10 (2.3%) were discharged home after a stay in ICU, 3 
(0.6%) died in ICU, 50 (11.4%) died in the general wards and 68 (15.5%) were transferred 
to a step-down hospital facility to complete their treatment.  The median duration of 
hospital stay was 7.0 days with an interquartile range of 4 to 10 days.   
 
Table 13. lists the admission diagnoses and organism/s cultured for the 13 HIV-infected 
children who were admitted to ICU.  Respiratory illness was the underlying diagnosis in 6 
of the 13 (46.1%) children admitted to ICU.  Only one out of the 13 ICU admissions was 
for a non-infectious illness (diabetic ketoacidosis.)
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Table 13.  Primary Diagnoses of 13 HIV-infected children admitted to ICU 
Primary Diagnosis Number      
(n = 13) 
Percent      
(% = 100) 
Organism/s 
Cultured 
Pneumonia - other than Pneumocystis jiroveci 
pneumonia (PJP) and pulmonary tuberculosis 
(pTB) 
2 15.4 E coli species 
PJP/presumed PJP 3 23 None 
Gastroenteritis 1 7.7 None 
Pulmonary TB (pTB)  1 7.7 None 
Septicaemia/UTI 1 7.7 Haemophilus 
influenza and 
Candida albicans 
Extrapulmonary TB (EPTB) 1 7.7 None 
Meningitis 1 7.7 Streptococcus 
pneumoniae 
Epiglottitis  1 7.7 None 
Diabetic ketoacidosis 1 7.7 None 
Pericardial effusion 1 7.7 None 
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Figure 8. illustrates the distribution of deaths by age category in months among the 53  
HIV-infected children who died.  The greatest number of deaths in HIV-infected children 
(28/53 [52.8%]) occurred in young infants less than 6 months of age. 
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Table 14. Case fatality rate by age group in HIV-infected admissions 
Age category Deaths / Category 
total number 
Percentage Case 
Fatality Rate 
95% Confidence 
Intervals 
Overall  
 
53/440 12  9.2–15.5 
<6mo 
 
28/166 16.9 11.5-23.5 
6-23mo 
 
13/116 11.2 6.1-18.4 
24-59mo 
 
4/60 6.7 1.9-16.2 
>60mo 
 
8/98 8.2 3.6-15.5 
 
HIV-related deaths contributed 53 of the total 91 deaths in the paediatric general wards 
during the study period (i.e. 58.2% of all paediatric deaths).  The overall case fatality rate 
in the study population of HIV-infected children was 53/440. (12.0% [95% CI 9.2–15.5%]) 
In contrast, the risk of mortality in the HIV negative, HIV-exposed and HIV unknown 
group over the study period was 38/1064. (3.6% [95% CI 2.5-4.9%])  The highest case 
fatality rate by age category, occurred in infants aged less than 6 months, with 28 deaths 
among 116 infants. (16.9% [95% CI 11.5-23.5%]) 
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Variables in the 53 children who died were compared to those in the 387 children who 
survived to hospital discharge to determine which features were associated with poorer 
outcomes. 
 
Table 15. Comparison of HIV-infected patient characteristics by final outcome  
Characteristic 
 
(Total n = 440) 
Outcome = 
Death 
(n = 53) 
Outcome = 
Survival  
(n=387) 
p-value Odds  
Ratio 
95% 
Confidence 
Interval 
Median age  
(IQR) 
     5 months 
(3 -13 mo.) 
12 months 
(4 – 48 mo.) 
0.2 - - 
Median weight for age 
z-score#   (IQR) 
-4.4 
(-4.9 to -3.0) 
-3.0 
(-4.1 to -1.7) 
0.005 - - 
Newly diagnosed 34/53 
(64%) 
204/387 
(52.7%) 
0.11 0.62 0.3-1.1 
Receiving ART 6/53 
(11.3%) 
70/368* 
(19%) 
0.17 0.54 0.2-1.3 
WHO HIV Stage 3  
or Stage 4 
50/53 
(94.4%) 
358/387 
(92.5%) 
0.62 1.35 0.4-4.6 
Median CD4 number  
(IQR) 
401 cells/ul 
(99-711) 
486 cells/ul 
(210-949) 
0.18 - - 
Median CD4%  
(IQR) 
13.9% 
(6.9-20.8%) 
15.2% 
(8.3-23.0%) 
0.32 - - 
Receiving CTX  
prophylaxis 
17/53 
(32.1%) 
148/387 
(38.2%) 
0.43 0.78 0.4-1.5 
 
# This calculation was only performed in patients aged 60 months or younger who had a 
documented weight in the hospital record, therefore in the death group n = 44 and in the 
survival group n = 303. * This denominator excludes patients who had received ART in the 
past, but were not receiving ART at the time of hospital admission and excludes patients 
who had inpatient initiation of ART. (n = 19) 
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There were no significant differences between median age, new HIV diagnosis, frequency 
of ART, WHO staging, immunological indices or frequency of CTX prophylaxis between 
HIV-infected children who died versus those who survived.  However, median weight for 
age z-score was significantly lower in the group of children who died versus those who 
survived. (p = 0.005)  
 
3.2.11 Cause of death in HIV-infected paediatric admissions at CHBH 
Infections were associated with all 53 deaths amongst HIV-infected children.  PJP, an 
illness largely preventable by CTX prophylaxis, accounted for 8/53 (15%) of all deaths.   
Figure 9 illustrates the proportional contribution of each aetiology.   
 
Figure 9. Causes of death in HIV infected children (n = 53)   
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3.2.12 Comparison of groups by ART status 
Differences in the subgroup of patients receiving ART at the time of hospital admission 
and the subgroup of ART-naive patients are tabulated below.  Children who had inpatient 
initiation of ART during the current hospital admission and children who had received 
ART in the past were excluded from this analysis. 
 
Table 16. Comparison of HIV-infected patient characteristics by population receiving 
ART versus ART-naive population  
Characteristic 
(Total n = 421) 
Receiving 
ART 
(n = 76) 
ART-naive 
(n = 345) 
p-value Odds 
Ratio 
95% 
Confidence 
Interval 
Median age  
(IQR) 
38 months 
(10.5 – 98 mo.) 
7 months 
(3 – 32 mo.) 
<0.0001 - - 
Median weight for age 
z-score (IQR)# 
-2.8 
(-4.1 to -1.6) 
-3.3 
(-4.4 to -1.9) 
0.32 - - 
Receiving CTX  
Prophylaxis 
71/76 
(93.4%) 
82/345 
(23.8%) 
<0.0001 0.01 0.002-0.04 
WHO HIV Stage 3  
or Stage 4 
75/76 
(98.7%) 
314/345 
(91.0%) 
0.02 0.14 0.02-0.09 
Median CD4 number 
(IQR) 
403 cells/ul 
(94-682) 
505 cells/ul 
(224-996) 
0.09 - - 
Median CD4%  
(IQR) 
13.3% 
(6.3-19.2%) 
15.9% 
(9.4-23.9%) 
0.008 - - 
Inpatient mortality 
rate 
6/76 
(7.9%) 
47/345 
(13.6%) 
0.17 - - 
Median duration of  
hospital stay 
6.5 days 
(4-10 days) 
7.0 days 
(4-10 days) 
0.93 - - 
# This calculation was only performed in patients 60 months of age or younger who had a 
documented weight in the hospital record, therefore in the ART treatment group n = 49 and 
in the ART-naive group n = 284.  
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Significant differences between the patients receiving ART and ART-naive patients 
included: median age (p=<0.0001); frequency of CTX prophylaxis age (p=<0.0001); 
median CD4 percentage (p=<0.008) and the proportion with WHO HIV stage 3 or 4 
disease. (p=0.02) 
 
The table below (Table 17.) compares the proportion of children who died that were 
eligible for ART with the proportion of children receiving ART at the time of their death.  
The calculation of eligibility for ART was based on the South African national guidelines
2
 
for paediatric ART initiation at the time of the study - using immunological and clinical 
(WHO staging) criteria only. 
 
Table 17. Eligibility for ART versus ART access in 53 HIV-infected children who died   
Age categories Number and 
proportion with 
CD4 percentage 
qualifying for 
ART* 
Number and 
proportion with 
WHO HIV stage 
qualifying for 
ART 
Number and 
proportion 
actually 
receiving ART 
at time of death 
All deaths 
(n = 53) 
18/27** 
66.7% 
50/53 
94.3% 
6/53 
11.3% 
Deaths < 18 months 
(n = 40) 
10/17** 
58.8% 
38/40 
95% 
6/40 
15% 
Deaths > 18 months 
(n = 13) 
8/10** 
80% 
12/13 
92.3% 
0/13 
0% 
* CD4 < 20% for children < 18 months old, CD4 < 15% for children > 18 months old 
** The denominators differ from the overall group denominators because only a proportion 
of the 53 children HIV-infected children who died had recent CD4 percentage results 
available.   
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4. Discussion and Conclusion 
4.1 Limitations 
1. The retrospective study design did not allow for assessment of in-hospital quality of 
care or evaluation of access to paediatric HIV services during and post-admission. This 
information would be useful in assessment and planning of paediatric HIV service 
delivery at CHBH, but this type of operational research would be best obtained by a 
prospective study design. 
2. Clinical data obtained for WHO HIV staging was subject to inter-observer variation as 
it had been collected by multiple doctors in the paediatric admission ward.  However, 
the study investigator used the WHO HIV staging reference to ensure consistency in 
assigning HIV staging based on the clinical data recorded (in cases where no HIV stage 
was documented.) 
3. The study site (tertiary hospital), small sample size, and limited time period limits the 
application of this study‟s findings i.e. it may not be appropriate to generalise the 
results of this study to the paediatric HIV population of Gauteng province. However the 
study provides a “snap-shot” of the impact of HIV on the paediatric wards at CHBH 
and in conjunction with previous studies can be used to inform planning of paediatric 
HIV service delivery at CHBH. 
4. The short time period of the study may overlook seasonal variations in the spectrum of 
illnesses diagnosed in our paediatric inpatient population. 
5. The data available on mothers‟ antenatal HIV status and usage of Nevirapine 
prophylaxis was limited – the PMTCT history was generally poorly documented in 
hospital files.  Recall bias with regard to NVP usage may also have been present. 
Further prospective studies to determine the uptake and efficacy of PMTCT at CHBH 
are urgently needed. 
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6. The lack of an HIV-negative comparison group is a shortcoming of this study, but is in 
part compensated by the comprehensive documentation and analysis of data on the 
HIV-infected group of children, as the latter was the main aim of this study. 
  
4.2. Strengths of the study 
1. A detailed record review was completed for each HIV-infected child. 
2. The study investigator was the only assessor for all of the hospital records thus ensuring 
consistency in completion of the study tool. 
3. From all 446 HIV-infected children admitted during the study period, only 6 records 
could not be located. 
4. Estimation of HIV prevalence was performed using data from both lab results and 
record review. 
5. Data from the study period compared favourably (in terms of total number of 
admissions and HIV-related mortality) with the CHBH basic ward statistics collected 
during the preceding three quarters of 2007. It is therefore likely to be a true 
representation of HIV-infected paediatric admissions at CHBH.   
 
In an attempt to contextualise the results of this study, the study period of the last quarter of 
2007 was compared to the first three quarters of 2007 (using CHBH paediatric 
departmental statistics.)  During the study period, 1510 paediatric admissions were 
recorded which compared closely to the 1677, 1542 and 1408 admissions in the first three 
quarters respectively.   
 
The number of deaths amongst HIV-infected children was similar during the study period 
(at 53 deaths/440 HIV-infected paediatric admissions [12%]) and during the first three 
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quarters of 2007 with 50, 45 and 51 deaths recorded amongst HIV-infected paediatric 
admissions. It is not possible to calculate case fatality rates among HIV-infected children 
for the first three quarters of 2007 because the denominator [total number of HIV-infected 
children admitted each quarter] is not available/not known. The proportional contribution 
of HIV-related deaths to the overall number of paediatric deaths in the general wards was 
higher at 58.1% (53/91 total deaths) during the study period, compared to 50.5% (50/99), 
46.4% (45/97) and 53.6% (51/95) during the first three quarters of 2007.   
 
As the Child PIP programme is adopted at more hospitals, including CHBH, data on 
countrywide paediatric HIV-related in-hospital mortality will become more readily 
available for comparison.  This study (with HIV-related deaths contributing 58.1% of all 
paediatric deaths) showed striking concordance with the South African national statistics 
from the Countdown to 2015 report which attributed 57% of all under-five mortality to 
HIV/AIDS.
43
 
 
4.3 HIV prevalence 
This study highlights the ongoing burden of disease from HIV-related paediatric 
admissions at CHBH and it is likely that this reflects the situation at many other state 
hospitals in South Africa.  The HIV prevalence amongst paediatric admissions during the 
study period was 29.5%, but this figure may have been higher since 15% of all admissions 
had no documentation of HIV testing (ie of unknown HIV status) and another 3.8% were 
HIV-exposed but had not yet undergone HIV PCR testing.   
 
Of the HIV unknown group of children, it is likely that the majority were not tested 
because they were considered highly unlikely to be HIV-infected, based on their history, 
  57 
nutritional status and clinical presentation.  However, it is possible that some children in 
this group were not tested because parental consent for HIV testing could not be obtained 
(in cases where parents were not available for counselling or where parents refused testing 
outright.)  However, this possibility could not be verified as documentation of reasons for 
not performing HIV testing in children of unknown HIV status was lacking in most clinical 
records. 
  
In the group of HIV-exposed infants who did not undergo HIV PCR testing during ward 
admission, the majority were less than 6 weeks of age.  Although data on the reasons for 
admission in the HIV-exposed group was not collected, these infants were presumably 
admitted with illnesses that may have been indicative of symptomatic HIV infection.  
Currently, South Africa‟s paediatric HIV testing protocols do not routinely recommend 
HIV PCR testing before 6 weeks of age.  It should be routine practice, however, to perform 
HIV DNA PCR for symptomatic HIV-exposed infants, in order to make an early diagnosis 
and expedite treatment for HIV-infected infants.
33
  It is of concern that very young infants 
are not being investigated for HIV even when sick enough to be admitted, particularly since 
HIV-exposure status is often unknown.      
 
Three previous studies at CHBH have assessed HIV ward prevalence and in-hospital 
mortality rates. Data from previous and current studies at CHBH is tabulated below (Table 
18.) in order to identify trends in the paediatric admission profiles. 
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Table 18.  HIV ward prevalence data from previous and current studies of paediatric 
admissions at CHBH 
 
*Mortality in this study considered all deaths in the HIV negative, HIV-exposed and HIV- 
unknown group.    
Study Period,  
Authors  
& Study Design 
Estimated HIV  
prevalence (%, 
absolute values 
and 95% CI) 
In-hospital  
mortality rate  
(HIV + children) 
In-hospital  
mortality rate   
(HIV - children) 
 
1992 – 1996 
Zwi et al.
17
 
Retrospective 
Increased from 
3% (120/3800) to 
19% (870/4694) 
- 
Increased from 
9.2% (11/120) to 
12.9% (112/870) 
- 
Decreased from 
5.4 % (80/1472) to 
4.5% (53/1187) 
- 
 
1996 
Meyers et al.
18
 
Prospective 
 
29% 
144/493 
(25.2-33.2%) 
 
16.5% 
17/103 
- 
 
4.6% 
15/326 
- 
2005 
Schneider et al.
19
 
Cross-sectional 
 
31.5% 
181/575 
- 
 
24.3% 
44/181 
- 
 
5.1% 
20/394 
- 
2007 
Dramowski et al.  
(this study – 
retrospective) 
 
29.5% 
446/1510 
(27.2 – 31.9%) 
 
12% 
53/440 
(9.2–15.5%) 
 
3.6%* 
38/1064 
(2.5-4.9%) 
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The HIV prevalence during the study period was very similar to the prevalence rate of 29% 
amongst hospitalized children at CHBH in the 1996 survey. 
18
   Thus several years after  
the national roll-out of the Department of Health‟s PMTCT and ART programmes, the 
paediatric HIV epidemic shows no evidence of a decreasing impact on paediatric hospital 
admissions.  
 
Possible reasons for this may include:  
1. An increased prevalence of HIV amongst women of childbearing age with 
consequently a larger number of HIV-infected infants born despite PMTCT 
interventions.  
2. In 2005 the HIV prevalence among paediatric admissions was 31.5%.  It is possible that 
even higher prevalence levels were reached during the period between 1996 and 2004 
and that the levels documented in 2005 and now in 2007 actually represent a decrease 
from a higher peak level. 
3. Improved survival rates (particularly in older HIV-infected children) may have resulted 
in more children surviving to hospital admission.  In the 1996 CHBH study, the HIV 
prevalence in hospitalised children was also 29%, but mortality rates were higher at 
17%. 
18
  Currently however, there may be a lower community-based prevalence of HIV 
but with increased numbers of hospital admissions, as HIV-infected children survive 
longer as a result of intervention programmes and provision of ART. 
 
Despite the static HIV prevalence figures, mortality rates appear to have dropped both 
among HIV-infected and HIV-uninfected children. There may be several explanations for 
this apparent trend including: earlier HIV diagnosis with improved awareness and 
  60 
availability of testing; improved access to ART with earlier age of ART initiation and in 
both groups, improved health services and nutritional status may play a role. 
 
4.4 Prevention of mother to child transmission (PMTCT) 
4.4.1 Poor record-keeping 
Of great concern is the fact that data regarding PMTCT interventions was very poorly 
documented by the admitting doctors in many patients‟ hospital records.  However, in 
instances where PMTCT history was specifically enquired about during admission history-
taking, many primary caregivers were unable to provide the required information and had 
no documentation of these interventions.  Owing to the limited availability of data, review 
of PMTCT interventions was restricted to the subgroup of HIV-infected infants under 6 
months of age, who were more likely to have PMTCT data recorded in their files.  It was 
also hoped that recall bias would be reduced by restricting PMTCT analyses to infants born 
less than 6 months ago.   
 
4.4.2 Maternal self-reported HIV status 
In the subgroup of HIV-infected infants under 6 months of age, only 54.2% of mothers 
self-reported their status as HIV positive at the time of their child‟s hospital admission. Of 
the remainder, 15.1% reported their status as HIV negative and 30.7% reported their status 
as HIV unknown or untested.  It is possible that some of the mothers who reported their 
status as HIV negative may have undergone seroconversion during pregnancy (after initial 
antenatal HIV testing.)  Others reporting their HIV status as negative or unknown may have 
been in denial or may have feared stigmatisation/prejudicial treatment if they had disclosed 
their status to health care workers.  
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In some cases where a child was known to be or newly diagnosed as HIV-infected, no 
maternal HIV test result could be located on the NHLS laboratory system or in the child‟s 
hospital admission file.  It is unclear whether the HIV-status of the mother was already 
known but not documented in the hospital file or if maternal HIV status was unknown and 
HIV testing for the mother had not been performed during the child‟s hospital stay.   Many 
of the mothers who reported their HIV status as negative or unknown would have been 
offered an HIV test in the paediatric wards, but their results were not always documented in 
their children‟s hospital records.  However, it is unfortunately not routine practise at CHBH 
to confirm a mother‟s HIV status (when she reports herself to be HIV-negative or HIV 
unknown) after her infant or child has been newly diagnosed as HIV-infected. 
 
4.4.3 Nevirapine exposure 
The overall frequency of reported NVP exposure as part of the PMTCT programme in 
infants under 6 months old was 36.2%.  Of infants born at CHBH, reported NVP exposure 
was marginally better at 51.8%.  For infants born elsewhere (clinic/other hospital/BBA 
combined – excluding those with unknown birthplace) reported NVP exposure was lower 
at 37.8%.  Thus it would appear that almost half of the CHBH-born infants (and almost 
two-thirds of infants born elsewhere) who presented for admission in their first 6 months of 
life had missed an opportunity to access NVP prophylaxis at birth through the existing 
PMTCT programme.   
 
There are many possible factors that contribute to poor uptake of NVP prophylaxis in HIV-
positive mothers.  Some of these factors could include: mothers who test at a clinic and 
then deliver in hospital; the HIV coding system used by midwives which is difficult to 
interpret; women‟s reluctance to disclose HIV status owing to stigma, poor transfer of 
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information between health facilities and a reluctance on the part of health care workers to 
offer all mothers HIV testing or to enquire about HIV status.   
 
Infants that had received NVP at birth were significantly more likely to be receiving CTX 
at the time of hospital admission compared with infants who had not received NVP or had 
unknown NVP exposure (p = 0.008.) This finding probably reflects better health seeking 
behaviour in this group of mothers.  It may also reflect linkages in the healthcare system 
(i.e. a note on the Road to Health Card [RTHC] regarding NVP administration at birth 
acting as a reminder to commence CTX at 6 weeks) and an opportunity for improving 
uptake of CTX prophylaxis (i.e. enforcing documentation of HIV-exposure and reminders 
for CTX prophylaxis and HIV PCR testing on the RTHC.) 
 
4.4.4 Cotrimoxazole prophylaxis 
Of the total subgroup of HIV-infected infants under 6 months, only 27.7% were reportedly 
receiving CTX prophylaxis at the time of hospital admission.  The reported CTX usage in 
infants born at CHBH (31.3%) was marginally better than CTX usage in infants born at 
clinics, other hospitals and unknown birthplace (combined).  Failure to provide CTX 
prophylaxis to HIV-exposed and HIV-infected infants represents a missed opportunity to 
prevent early mortality from Pneumocystis jirovecii pneumonia.  High loss to follow-up of 
HIV-exposed infants is a  major problem in the PMTCT programme both at CHBH and at a 
national level as reported by previous studies.
27, 28
   
 
4.4.5 Missed opportunities for PMTCT interventions 
PMTCT interventions in the subset of infants less than 6 months old were analysed taking 
into consideration the self-reported HIV status of their mothers. The mothers who reported 
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their status as HIV-infected would have been expected to have benefited from access to the 
PMTCT programme.  However, only 66.7% of these mothers received NVP and only 
38.9% of their infants received CTX prophylaxis.   Of these same infants, only 41.1% had 
been HIV PCR tested and diagnosed HIV-infected prior to hospital admission.  The 
remainder, although known to be HIV-exposed, were not tested for HIV until they were ill 
and required admission in the CHBH paediatric wards.  Of the infants known to be HIV-
infected at the time of hospital admission, only 32.4% were accessing ART.  Based on the 
findings of the CHER Study
33
, the WHO has recommended that all HIV-infected infants be 
fast-tracked for ART.
44
  In view of the high case fatality rate among infants less than 6 
months of age documented by this study, the provision of early ART to HIV-infected 
infants should be prioritized at CHBH. 
  
A similar sub-analysis for infants whose mothers reported their own status as HIV negative 
or HIV unknown demonstrated even greater numbers of missed opportunities for PMTCT 
intervention.   As illustrated in Figures 3 and 4, poor uptake of VCT at antenatal clinics, 
lack of repeat HIV testing in labour, poor uptake of NVP prophylaxis and lack of infant 
follow-up for CTX prophylaxis and PCR testing represent missed opportunities for the 
prevention of paediatric HIV.   An analysis of access to PMTCT for HIV-exposed, HIV- 
negative and HIV-unknown infants is required, but was beyond the scope of this study. 
 
In general, uptake of all PMTCT interventions among the 166 infants less than 6 months 
old was poor.  Seventy-six (45.8%) of all 166 infants less than 6 months of age received no 
PMTCT interventions whatsoever and only 20/166 (12%) of infants received all 
recommended interventions (NVP, CTX, early HIV PCR testing.)  The fifth perinatal care 
survey of South Africa (2003-2005) identified several weaknesses in the PMTCT 
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programme which could result in missed opportunities for paediatric HIV prevention 
including: overemphasis on prevention of vertical HIV transmission without inclusion of 
strategies for child survival i.e. feeding support, HIV PCR testing and referral for ART 
where indicated; poor uptake of maternal antenatal HIV testing because of opt-in testing 
policies; reluctance of midwives to take responsibility for establishing maternal HIV status 
and limited participation of mothers in feeding choices.
45
 
 
4.5 Nutritional status and HIV staging 
As expected, a significant proportion of HIV-infected children were malnourished when 
assessed by means of the Wellcome classification.  Unfortunately length for age/height for 
age and height for weight analyses (to assess for stunting and wasting) could not be 
performed because many hospital records had no data on height documented. 
 
Assessment for evidence of malnutrition is also an integral part of the WHO HIV staging 
system. Therefore clinicians, particularly those working in the outpatient setting, should 
encourage routine HIV testing of all malnourished children in order to maximise the HIV 
detection rate.  This study confirmed that most HIV-infected patients present with 
advanced disease (92.7% had stage 3 or 4 disease) and consequently more severe illnesses 
and poorer outcomes.  This finding reinforces the need to identify infected children earlier 
in the course of their disease.  This will require intensified follow-up of all children 
receiving routine child health care and intensified follow-up of all children whose mothers 
received PMTCT care.  This follow-up should commence from as early as 4-6 weeks after 
birth and should continue monthly in the first year of life (given the high incidence of 
admissions in those under six months.)   
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Preliminary results form the Children with HIV Early Antiretroviral Therapy (CHER) trial 
show that HIV-exposed infants are at risk for disease and death early on (even if 
asymptomatic and even with high CD4 percentages).
33
  These results imply that all infants 
in high prevalence areas should be tested for HIV, especially young infants who present 
unwell at a health service.  Based on these significant findings the WHO has recently 
released (May 2008) revised Paediatric treatment recommendations and the Paediatric 
subcommittee of the Southern African HIV Clinicians Society has issued an Advisory 
statement (June 2008).
46
  Both of these recommendations call for treatment of all HIV-
infected infants irrespective of CD4 percentage or count. 
 
4.6 Antiretroviral treatment (ART) 
Of the 364 (82.7%) HIV-infected children not receiving ART at the time of hospital 
admission, 346 (95%) qualified for HAART based on current WHO clinical and 
immunological guidelines.  Of these 346 children who qualified for ART, only 15 children 
(3.4%) were able to initiate inpatient ART.  Multiple hurdles to inpatient ART initiation 
exist, such as absence of the primary caregiver, poor social circumstances, the severity or 
nature of the child‟s illness and clinician inexperience with or reluctance to commence 
HAART in the inpatient population.  Despite these obstacles, many more children could be 
prepared for, or commenced on, ART during ward admission.   
 
Most newly-diagnosed HIV-infected children are seen by clinical staff from the hospital-
based HIV service (Harriet Shezi Children‟s Clinic), whilst admitted in the wards in order 
to begin preparations for ART.  Once discharged from hospital, a follow-up appointment is 
booked at the clinic to complete pre-treatment investigations and counseling.  However, in 
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view of the fact that 95% of the paediatric admissions at CHBH qualify for ART, there is 
an urgent need to expedite inpatient commencement of ART.   
 
This recommendation is given further impetus in light of the preliminary findings of the 
CHER study that showed a 75% reduction in mortality with early ART initiation in 
children.
33
  In view of this dramatic finding, our current national treatment guidelines are 
probably too conservative, resulting in delayed initiation of HAART and consequently 
excess infant mortality.  
 
4.7 Immunological indices  
Recent (within a month of hospitalization) CD4 percentage and cell count test results were 
available for a subset of the study population (320/440 and 312/440.)  These indices 
confirmed that the majority of children had moderate to severe immunosuppression at the 
time of hospital admission.  This finding was not unexpected in light of the fact that over 
90% of children presented with advanced HIV disease.  Of note is that in the subgroup of 
infants aged less than 6 months, 65.5% had CD4 percentages below the WHO‟s 
recommended 25% cut-off for ART initiation, yet only 7.2% were receiving ART at the 
time of hospital admission.   
 
The remaining 34.5% of infants aged less than 6 months, had CD4 percentages >25% but 
were symptomatic from their HIV disease and required hospital admission.  This finding 
emphasizes the fact that CD4 percentage is not reliably predictive of disease severity in 
young infants.  Thus it is hoped that new national guidelines recommending ART initiation 
for infants with CD4 percentages < 35% or WHO stage 2 or greater, will be published 
soon. 
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4.8 Primary diagnosis 
As expected, infections were the most common reason for hospital admission.   Respiratory 
illnesses (pneumonia, PJP and pulmonary TB) accounted for 46.4% of all admission 
diagnoses.  In most cases the diagnosis of PJP was presumptive (based on clinical 
presentation), owing to the difficulties in collecting nasopharyngeal aspirates on admission 
and the poor sensitivity of immunofluorescent staining tests.  Commencement of TB 
treatment was done empirically in most cases given the well-described difficulties of 
confirming TB disease in HIV-infected children. 
47
 
 
In the group of children on ART, 10.5% of children (8/76) were admitted with a primary 
diagnosis of IRIS on clinical grounds.  However, this point prevalence does not take into 
account the relevant denominator ie. the entire pool of children commenced on ART at the 
Harriet Shezi Childrens Clinic.  There is limited data available on the prevalence of IRIS in 
HIV-infected children commenced on ART (both at national and international level.) 
48
  In 
our setting, we feel that many cases of paediatric IRIS remain undiagnosed either because 
clinicians are not familiar with the presentation of IRIS or because some children may 
demise at home or in other institutions.  
 
4.9 Spectrum of infectious pathogens 
A quarter (110/440) of the study population had a confirmed bacterial, viral, protozoal or 
fungal infection during their hospital admission.  A wide spectrum of pathogens were 
encountered, but notably, Streptococcus pneumoniae was the most commonly cultured 
bacterium overall.  Streptococcus pneumoniae was also the most common bacterial isolate 
in children who died.  This result is of public health significance because infection with this 
organism is potentially vaccine-preventable in HIV-infected children. 
49
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Cytomegalovirus infection was confirmed in 14 cases and disseminated CMV disease was 
responsible for 5 of the 53 deaths in HIV-infected children (9.4%).  Some cases of CMV 
infection were confirmed on post-mortem histology of lung and/or liver biopsies and the 
remainder by a positive pp65 antigen test in combination with a compatible clinical picture.   
 
Of the 53 children who died, 24 (45.3%) had a confirmed infection at the time of death.  
Also of note was that 48% (36/75) of bacterial isolates from blood, urine or CSF cultures 
were fully or intermediately resistant to one or both of the first-line antibiotics used at 
CHBH in HIV-infected children.  Typically, organisms such as E coli ESBL, Klebsiella 
ESBL, Methicillin resistant Staphylococcus aureus (MRSA), Pseudomonas, Salmonella 
species and Staphylococcus aureus are not sensitive to empiric treatment with Ampicillin 
and Gentamicin.  Thus we should have a low threshold for initiating second line antibiotic 
regimens utilising broad-spectrum antibiotics (based on local antibiotic resistance patterns) 
in critically ill HIV-infected children who do not respond clinically to initial therapy or 
who may have acquired resistant nosocomial bacterial infections.  
 
4.10 Outcome 
4.10.1 Contribution of HIV-related deaths to overall paediatric mortality 
Most notable was the fact that HIV-infected children had a case fatality rate more than 
threefold greater than that of the HIV negative, HIV-exposed and the HIV unknown group 
(12% % [95% CI 9.2–15.5]) vs. 3.6% [95% CI 2.5-4.9]). HIV-related deaths were the 
single largest group, contributing 58.1% of all paediatric deaths in the general wards during 
the study period.  As mentioned previously, this is in line with national estimates from the 
Countdown to 2015 report which attributed 57% of all under-five mortality to HIV/AIDS. 
43
 
  69 
4.10.2 Outcome in young infants 
Infants less than 6 months of age were at highest risk of death with a case fatality rate of 
16.9% (95% CI 11.5-23.5).  Over half of these infants under 6 months of age (50.8%) 
qualified for ART based on our national guidelines for initiating ART in infants with CD4 
counts less than 20%.  If WHO immunological criteria (CD4 < 25%) are used, 65.5% of 
this group qualified for ART.  Despite the fact that the majority of infants less than 6 
months old qualified for ART, only 7.2% of this group was receiving ART at the time of 
hospital admission.   
 
A high mortality in young infants has been documented in the CHER study where even 
infants who were clinically well and had high CD4 percentages, had an excess mortality 
compared to their counterparts who started ART early.
33
  In other cohorts, up to 50% of 
children die before 2 years of age.
50
  In order to address the high mortality recorded in this 
age group, we need to prioritise early diagnosis and fast-tracking of infants for ART.  
 
4.10.3 Outcome of ICU intervention in HIV-infected children  
During the study period only 13 children (3.0%) were admitted to ICU or ventilated in the 
high care area of the acute admissions ward.  Of these 13 children, 10 (76.9%) survived to 
hospital discharge and 3 (23.1%) died in ICU or high care.  Overall, a 76.9% ICU/high care 
survival rate in HIV-infected children appears surprisingly good.  However, data were not 
analysed or were not available to consider how these ICU candidates were selected and 
how their duration of stay, incidence of complications and long-term morbidity and 
mortality compared with that of HIV negative children admitted to ICU.   
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At present, in view of the high demand for intensive care facilities, many critically-ill HIV-
infected children at CHBH cannot be accommodated in the ICU.  Further studies are 
required to evaluate current policies and outcomes of HIV infected children admitted to 
ICU – especially now that ART is more accessible – with a view to developing consensus 
guidelines for the admission of HIV-infected children to ICU. 
 
4.10.4 Step-down care at CHBH 
A substantial proportion of HIV-infected children (15.5%) were transferred to a step-down 
hospital facility after stabilisation, investigations and interim management were completed, 
in order to reduce the burden on overcrowded paediatric wards at CHBH.  The outcomes of 
these children are unknown.  Of concern with this practice of down-referral is that in some 
cases, children may be transferred before HIV testing results have been confirmed and 
before post-test counseling of parents has occurred.  This results in missed opportunities for 
diagnosis and further delay in referral of HIV-infected children for commencement of 
ART. 
 
4.10.5 Comparison of HIV-infected patient characteristics by final outcome 
Median weight for age z-scores were significantly lower in the group of children who died 
versus those who survived, reinforcing the observation that poor nutritional status is 
associated with poorer outcomes among hospitalised children.  Thus particular attention 
should be paid to nutritional rehabilitation of ill, hospitalised HIV-infected children. 
  
Although the difference in median age between children who died and those who survived 
was not significant, it is important to note that most deaths occurred in early infancy.   
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This implies that ART initiation in infants should be fast-tracked in order to prevent or 
reduce early mortality in this age group of HIV-infected infants.     
 
Also of note is the observation that there was no statistically significant difference between 
children who died versus those who survived in terms of HIV Stage and CD4 number or 
percentage.  This observation is valuable in reinforcing the fact that CD4 count is a poor 
predictor of HIV disease progression and risk of death, especially in infants.
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ART status was not associated with outcome (death vs. survival), however, the median 
duration of ART in the treatment group was only 2 months and thus any real effect on 
survival in the ART group would have been limited.  Interestingly, only 1 death was 
recorded in the group of children that had received ART for more than 6 months (n = 
30/76), whereas there were 5 deaths in children that had received ART for less than 6 
months. (n = 46/76) [p =0.23]  Further studies are required (with larger numbers of children 
who have been established on ART for 6 or more months) to show a statistically significant 
association between ART and survival benefit in hospitalised HIV-infected children.   
 
Anecdotally, there has been an impression in clinical out-patient practice (at Harriet Shezi 
Children‟s Clinic) that the number of HIV-infected children established on ART requiring 
hospital admission has decreased.  Thus the fact that this study did not show a statistically 
significant association between ART and survival in hospitalised HIV-infected children, 
may relate more to the fact that the children who were admitted reflected the sickest 
children with the most advanced disease course and shorter duration of ART. 
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4.11 Comparison of HIV-infected patient characteristics by ART status 
The group of children on ART were significantly older than the ART-naïve group (median 
age 38 versus 7 months.)  This highlights the fact that few children admitted at CHBH have 
had the benefit of early ART initiation.   
 
Children with advanced HIV disease were more likely to be receiving ART at the time of 
hospital admission (p =0.02).  However, in the ART-naïve group, 91% of children 
presented with WHO stage 3 or 4 HIV disease and thus already qualified for ART 
initiation.   
 
Interestingly, children accessing ART had a significantly lower median CD4 percentage 
than children who were ART-naïve.  This probably reflects the fact however, that the most 
immunosuppressed children are commenced on ART earlier and that their CD4 counts take 
time to improve on ART. (The median duration of ART in the 76 children receiving 
treatment at the time of hospital admission was only 2 months.) CD4 counts may also be 
transiently lowered during opportunistic infections and this may explain the low counts 
observed in the study population who were being admitted during periods of illness.  
However, one would expect this to affect both the group of children on ART as well as the 
ART-naïve, and thus does not fully explain the difference in median CD4 percentages. 
 
Children on ART were much more likely to be receiving CTX prophylaxis (93.4 vs 
23.8%), which aside from the ART itself, may have contributed to the lower case fatality 
rate in this group (p < 0.0001).  Although a lower inpatient case fatality rate was recorded 
amongst children on ART versus the ART-naïve group, this finding was not statistically 
significant. (p = 0.17)  However, the median duration of ART in the treatment group was 
  73 
only 2 months and a longer observation period on ART may be needed to demonstrate 
survival benefit in the ART group. 
 
There was no significant difference in the median duration of hospital stay between the 
group on ART and the ART-naive.  In the future, however, it is hoped that increasing rates 
of paediatric ART coverage will reduce the HIV-related case burden at CHBH.  Further 
studies are warranted to assess the impact of ART on rates of re-admission in the paediatric 
wards at CHBH. 
 
4.12 Eligibility for ART in HIV-infected children who died   
Table 17. compared the proportion of children who died that were eligible for ART (based 
on immunological and clinical criteria) with the proportion of children receiving ART at 
the time of their death.  This data reinforces the fact that the majority of children who died 
during the study period qualified for ART initiation on immunological and clinical 
grounds.  Overall, 94.3% of the children who died had advanced HIV (WHO stage 3 or 4 
disease.)  Of the children under 18 months of age, 58.8% qualified for ART based on a 
CD4% < 20% but only 15% were accessing ART.   Of children over 18 months of age, 
80% qualified for ART based on a CD4% < 15% but not one child in this group was 
accessing ART, despite 53.8% of these children being previously diagnosed as HIV-
infected. (ie. known cases)   
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4.13 Conclusion 
In 2006, HIV/AIDS related deaths accounted for 57% of under-five mortality in South 
Africa.
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   The paediatric HIV epidemic in South Africa has seen a reversal of the past 
advances made in childhood mortality rates.  Without a co-ordinated approach to 
prevention, early detection and comprehensive care of paediatric HIV, our country cannot 
hope to achieve the Millennium Development Goal of a two-thirds reduction in child 
mortality by 2015. 
 
This retrospective, descriptive study with analytic elements determined a 29.5% prevalence 
(95% CI 27.2 – 31.9%) of HIV infection amongst paediatric admissions at CHBH and 
described the clinical profile and outcome of 440 HIV-infected children.  Of these children, 
54.1% were newly diagnosed with HIV. Only 19% of children had a normal weight.   
 
Uptake of PMTCT interventions among infants less than 6 months old was poor, with 
76/166 (45.8%) receiving no PMTCT interventions whatsoever. Multiple missed 
opportunities for the prevention and treatment of paediatric HIV were highlighted 
including: lack of antenatal HIV testing; poor uptake of NVP prophylaxis; lack of infant 
follow-up for CTX prophylaxis and HIV PCR testing.  
 
Infection, especially pulmonary infection, was the principal reason for hospitalisation.  
Despite the majority (92.7%) of admissions having advanced HIV disease (WHO Stage 3 
or 4), only 17% were accessing ART.  The overall case fatality rate was 12% (95% CI 9.2-
15.5), with deaths in HIV-infected children contributing 58% of all deaths in the general 
paediatric wards. Over half (52%) of all deaths in the HIV-infected group occurred in 
infants younger than 6 months of age. 
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HIV infection is the major contributor to morbidity and mortality among paediatric 
admissions at CHBH.  Poor uptake of PMTCT interventions, late diagnosis of HIV 
infection and slow rollout of ART are barriers to improved care in HIV-infected children at 
CHBH.  Based on these findings, several pragmatic recommendations have been made 
which aim to improve management of paediatric HIV at CHBH.  The goal of achieving 
maximal PMTCT coverage at CHBH must be prioritised.  In order to reduce paediatric 
HIV-related mortality at CHBH, efforts should focus on early diagnosis of HIV infection 
and prompt initiation of ART in infants under 6 months of age.  
 
Key research questions identified by this study include the need for prospective, 
operational research around the following problems: apparent poor uptake of PMTCT 
services at CHBH; maternal non-disclosure of positive HIV status; poor access to/under-
utilisation of ART services. Another key area to research is identification of barriers to 
inpatient ART initiation and evaluation of treatment outcomes (clinical and virological) 
among children who commence ART in the wards.  An audit of the paediatric HIV services 
at CHBH, including long-term data on the impact of ART initiation on ward admission 
profiles is also needed.  Ongoing surveillance of HIV prevalence and disease profile will 
help us to determine whether our efforts in PMTCT and ART provision will achieve a 
decrease in paediatric HIV-related admission and mortality rates at CHBH in the future. 
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4.14 Recommendations for improving management of paediatric HIV at CHBH 
based on the findings of this study:  
A. Recommendations for practitioners/clinicians at CHBH (hospital level) 
 Improve paediatric HIV-related history taking: Train all ward doctors to take a 
comprehensive perinatal history including PMTCT interventions (maternal HIV status, 
maternal ART or NVP/AZT prophylaxis, infant NVP/AZT prophylaxis and CTX usage, 
HIV PCR testing, WHO HIV staging, previous ART regimens etc) in the admission 
clerking notes of every child. 
 Improve documention of HIV status in inpatient and outpatient records: 
Document NVP and AZT, CTX prophylaxis and HIV PCR testing results on every HIV-
exposed child‟s RTHC and handheld hospital record. 
 Facilitate early diagnosis of HIV: Perform HIV PCR testing on any HIV-exposed 
„symptomatic‟ infant in CHBH outpatient clinics and all infants admitted to the wards, 
even if less than 6 weeks of age.  
 Ensure mothers (parents) are also tested for HIV: In mothers of unknown HIV 
status presenting with infants at the CHBH paediatric outpatient department or wards, offer 
rapid HIV testing to the mother and HIV PCR testing for the infant if mother‟s rapid HIV 
test is positive.  
 Reduce numbers of HIV-exposed CHBH-born babies who are lost to follow-up: 
Provide routine referral of all HIV-exposed infants for HIV PCR testing from 6 weeks of 
age (or earlier if symptomatic) as is currently occuring between the CHBH maternity wards 
and the Nurses Home at the Perinatal HIV Research Unit.   At this visit for HIV PCR 
testing, a sufficient supply of CTX should be issued to last until the next visit for PCR 
results. (A proforma referral letter with the date and place of appointment should be issued 
on discharge from maternity or neonatal ward.) 
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 Scale-up paediatric ART initiation in the wards: Prepare more children for ART as 
inpatients and increase the rate of inpatient ART initiation at CHBH. 
 Ensure continuity of care for HIV-infected children: Ensure that wherever possible, 
no child is discharged or transferred to step-down hospital facilities before HIV test results 
have been conveyed to the primary caregiver, in order to avoid missed opportunities in 
diagnosis and referral.  If a child known to be HIV-infected and not normally resident in 
the CHBH drainage area is discharged, ensure that a referral letter and appointment date is 
given for a paediatric ART clinic in the child‟s are of normal residence.   Improve 
communication with step-down facility so that children are not lost to follow-up when 
discharged (preferably a booking should be made at an ART clinic with the family contact 
details provided before any child is sent to step-down facility.) In the event that a child has 
to be referred, it is incumbent on the referring doctor to ensure that the child‟s HIV results 
are communicated (and such communication documented) to the referral site. 
 Reduce loss to follow-up of children diagnosed as HIV-infected in the wards: 
Ensure that every HIV-infected child discharged from the CHBH general paediatric wards 
or short-stay wards has written confirmation of a HIV clinic follow-up appointment date so 
as to expedite the process of preparation for ART. 
 
A paper authored by several local experts on paediatric HIV, recommended similar 
interventions to improve PMTCT and to scale-up paediatric diagnosis and ART services. 
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B. Recommendations for policy-makers at CHBH (hospital level) 
 Recommend routine recording of NVP and AZT prophylaxis on every HIV-exposed 
child‟s RTHC and CHBH handheld hospital record. 
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 Implement mandatory repeat maternal HIV testing shortly before delivery in CHBH 
labour ward, to identify mothers who have recently seroconverted.  
 Recommend HIV testing of women in postnatal wards in cases where a mother was not 
tested antenatally or had tested HIV-negative more than six weeks prior to delivery.   
 Review all existing data on PMTCT interventions at CHBH to identify and address 
programmatic deficiencies. 
 Join the list of hospitals that contribute mortality data to the CHIP database, so that data 
from paediatric ward outcomes at CHBH can be used to assist with paediatric health 
service auditing and planning.  
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6. Appendix 1:  STUDY TOOL    DOA: ____/_____/____     Study no: ______________     
A DEMOGRAPHICS     
1. Age in months     
2. Gender (1=male; 2=female)    
B HIV TESTING 1 = yes    2 = no 9 = 
unknown 
  
3. Child newly diagnosed HIV+ during this 
admission? 
     
C PMTCT DETAILS   1 =  
positive 
2 =  
negative 
9= 
unknown 
  
4. Self-reported HIV status of the biological 
mother? 
     
  1 =  yes 2 =  no 9 = 
unknown 
  
5. NVP prophylaxis to mother in labour and/or 
child at birth? 
     
  1 =  
CHBH 
2 =  
clinic 
3 = other 
hosp 
4 = 
 BBA 
9 = 
unknown 
6.  Place of birth:      
D HIV MANAGEMENT 1 = 
 never  
Rx 
2= 
previous 
ART 
3 =  
current 
ART 
4= 
inpatient 
ART 
9 = 
unknown 
7. ARV treatment history:       
  1 = yes 2 = no 9 = 
unknown 
  
8. If not on ARVs, does child currently need 
ARVs? 
     
9. If on ARVs, no. of months on treatment:      
  1 = yes 2 = no 3 = not 
indicated 
9 =  
unknown 
 
10. Child on CTX prophylaxis at time of 
admission? 
     
E GROWTH PARAMETERS       
11. Weight (kg)      
12. Length / Height (cm)      
13. % expected wt for age      
14. % expected ht for age      
  1 = 
normal 
2 =  
UWFA 
3 =  
marasmic 
4 =  
kwash 
5 =  
mar.kwash 
15.  Wellcome classification      
F HIV STAGING 1 =  
stage 1 
2 =  
stage 2 
3 =  
stage 3 
4 =  
stage 4 
16. WHO clinical stage     
17. Criteria for staging     
G IMMUNOLOGICAL STATUS     
18. CD4 count : #     
19. CD4 count : %     
H ADMISSION DIAGNOSES  
20. Diagnosis 1 
 
1=pneumonia   2=PJP   3=CMV pneumonitis 5=pTB empiric   
6=pTB confirmed   7=gastroenteritis   8=EPTB    
9=septicaemia   10=IRIS   11=anaemia   12=CLD 13=cor 
pulmonale   14=meningitis   15=UTI   16=RVD encephalopathy 
20=other 
21. Diagnosis 2 
22. Organism 
 
 
I CLINICAL OUTCOME  
23. 1 = Discharged home – no ICU admission 
2 = Discharged home after ICU admission 
3 = Died in ICU  
4 = Died in ward 
5 = Refused hospital treatment  
6 = Transferred back to referring hospital  
7 = Transferred to step-down hospital facility  
 
J  DURATION OF HOSPITAL STAY       dd/mm/yy 
24. date   Date of admission            /      / 
25. Date of final outcome           /      / 
26. Stay (number of nights)  
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Appendix 2: WHO HIV Staging Criteria 
Stage 1 
Asymptomatic 
Persistent generalised lymphadenopathy 
 
Stage 2 
Hepatosplenomegaly 
Recurrent or chronic RTI (otitis media, otorrrhoea, sinusitis) 
Papular pruritic eruptions 
Seborrheic dermatitis 
Extensive human papilloma virus infection 
Herpes zoster 
Fungal nail infections 
Recurrent oral ulcerations 
Angular cheilitis 
Parotid enlargement 
Lymphoid Interstitial Pneumonitis 
Recurrent or severe bacterial infection 
 
Stage 3 
Failure to thrive (60-80% expected body weight) 
Oral candidiasis beyond the neonatal period 
Unexplained chronic diarrhoea (>2 weeks) 
Unexplained persistent fever 
Pulmonary TB 
Severe recurrent presumed bacterial pneumonia 
Unexplained anaemia (<8g/dl), neutropaenia (<500/mm
3
), throbocytopaenia (<50 000/mm
3
) 
for more than one month 
Chronic HIV-associaed lung disease including brochiectasis 
Symptomatic lymphoid interstitial pneumonitis 
 
Stage 4 
Severe failure to thrive (<60% expected body weight) 
Pneumocystis pneumonia 
Recurrent severe presumed bacterial infections (excluding pneumonia) 
Chronic herpes simplex infection > 1 month 
Extrapulmonary TB 
Kaposi‟s sarcoma 
Oesophageal candidiasis 
CNS toxoplasmosis 
HIV encephalopathy 
CMV infection 
Extrapulmonary cryptococcosis 
Any disseminated endemic mycosis 
Cryptosporidiosis, Isosporiasis 
Disseminated non-tuberculous mycobacterial infection 
Candida of trachea, bronchi, lungs 
Visceral HSV 
Acquired HIV-associated rectal fistula 
Non-Hodgkins lymphoma 
PML 
HIV-associated cardiomyopathy or nephropathy 
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